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ABSTRACT 
Canavan’s Disease is a fatal Central Nervous System disorder caused by genetic defects 
in the enzyme – aspartoacylase and currently has no effective treatment options. We 
report additional phenotypes in a stringent preclinical aspartoacylase knockout mouse 
model. Using this model, we developed a gene therapy strategy with intravenous 
injections of the aspartoacylase gene packaged in recombinant adeno associated viruses 
(rAAVs). We first investigated the CNS gene transfer abilities of rAAV vectors that can 
cross the blood-brain-barrier in neonatal and adult mice and subsequently used different 
rAAV serotypes such as rAAV9, rAAVrh.8 and rAAVrh.10 for gene replacement 
therapy. A single intravenous injection rescued lethality, extended survival and corrected 
several disease phenotypes including motor dysfunctions. For the first time we 
demonstrated the existence of a therapeutic time window in the mouse model. In order to 
limit off-target effects of viral delivery we employed a synthetic strategy using 
microRNA mediated posttranscriptional detargeting to restrict rAAV expression in the 
CNS. We followed up with another approach to limit peripheral tissue distribution. 
Strikingly, we demonstrate that intracerebroventricular administration of a 50-fold lower 
vectors dose can rescue lethality and extend survival but not motor functions. We also 
study the contributions of several peripheral tissues in a primarily CNS disorder and 
examine several molecular attributes behind pathogenesis of Canavan’s disease using 
primary neural cell cultures. In summary, this thesis describes the potential of novel 
rAAV-mediated gene replacement therapy in Canavan’s disease and the use of rAAVs as 
a tool to tease out its pathological mechanism. 
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CHAPTER I: INTRODUCTION 
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CHAPTER I: Introduction 
Canavan Disease 
Canavan disease [CD] is a fatal pediatric leukodystrophy in which the Central 
Nervous System [CNS] white matter shows progressive spongy degeneration. It results 
from deficiency of aspartoacylase [N-acetyl-L-aspartoacylasertate amidohydrolase; EC 
3.5.1.15] (Matalon et al., 1988), an enzyme required for catabolism of N-acetylaspartate 
(NAA), the second most abundant amino acid derivative in the CNS.  
Clinical Presentation 
The first CD patient was reported by Myrtelle Canavan (Canavan, 1931) 
describing a prominent enlargement of the head and cerebral and cerebellar spongy 
degeneration as “Schilder’s encephalitis periaxialis diffusa” which was later acclaimed as 
a clinical entity (Van Bogaert L, 1949). Three clinically distinct variants exist (Adachi et 
al., 1973) namely:  
─ Congenital form: severe symptoms recognizable in the first few weeks of life,  
─ Infantile form: most common form where symptoms appear by 6 months of age  
─ Juvenile form: mildest form in which symptoms manifest by age 4 or 5.  
These early reports included a comprehensive description of the clinical and 
pathological features of the disease and the predilection for its occurrence in Ashkenazi 
Jews of Eastern European extraction. Currently however a growing number of non-
Jewish patients have been identified worldwide (Elpeleg and Shaag, 1999; Mizuguchi et 
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al., 2009; Stenson PD, 2003; Unalp et al., 2008; Zeng et al., 2006a; Zeng et al., 2006b; 
Zhang et al., 2010). 
Patients show vacuolization in the subcortical white matter (which becomes 
gelatinous), edema and demyelination and thin delicate meninges. Swollen cortical 
protoplasmic astrocytes containing membrane-bound cytoplasmic vacuoles, elongated 
mitochondria with distorted cristae, degraded axonal medullary sheaths and a prominent 
increase in protoplasmic astrocytes characterize the diseased brain. There also seems to 
be a significant loss of proteolipid protein and lipids in the white matter (Beaudet, 2001). 
Clinical manifestations include weak neck muscles, loss of muscle tone, severe 
psychomotor and mental retardation, seizures, NAAduria, blindness and megalencephaly.  
Characterization of the enzyme: Aspartoacylase 
CD was described as an enzyme deficiency disease (Matalon et al., 1988) when 
NAA-rich patient plasma and urine samples were incubated with normal fibroblasts 
extracts and subsequently showed increased aspartate levels suggesting a block in NAA 
catabolism in patients. Intensive genetic studies identified human aspartoacylase cDNA 
from kidney based on sequence information from bovine aspartoacylase. The gene was 
localized to 17p13-ter, comprises 6 exons encoding a 313 amino acid long polypeptide 
chain with a molecular mass of 36kD (Kaul et al., 1993). Aspartoacylase deacetylates 
NAA (Birnbaum et al., 1952 ) with a Km of 8.5 x 10
-4 mol/L and Vmax of 43000 nmol/min 
per mg of protein (Kaul et al., 1991). Isolation of the aspartoacylase cDNA sequence led 
to identification of causative mutations for CD and hence was a landmark in the field as it 
made molecular diagnosis and gene therapy of CD possible (Kaul et al., 1994). Currently, 
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>54 mutations are associated with Canavan disease (Hershfield et al., 2007) with new 
mutations being identified on a regular basis. Transient transfection of COS cells shows 
that only some missense mutations in the ASPA gene have negligible aspartoacylase 
activity (Hershfield et al., 2007).  
Genetic analyses have identified two major CD mutations in Ashkenazi Jewish 
patients namely a missense mutation in codon 285 [exon VI] causing substitution of 
glutamic acid to alanine. It accounts for 83.6% mutations identified in 104 alleles from 52 
unrelated Ashkenazi Jewish patients (Kaul et al., 1994). Another one is a nonsense 
mutation on codon 231 [exon V] which converts tyrosine to a stop codon, found in 13.4% 
of the alleles from Jewish patients (Kaul et al., 1994). Among non-Jewish patients, the 
mutations are more diverse, the most common being a missense mutation substituting 
alanine for glutamic acid in codon 305. This mutation was observed in 35.7% of the 70 
alleles from 35 unrelated non-Jewish patients (Kaul et al., 1994). The diverse mutations 
associated with CD limit the use of DNA analysis for prenatal diagnosis to known 
carriers with previously described mutations are among those that are known. Patients 
seem to follow a similar course of disease irrespective of residual aspartoacylase activity. 
For instance, children carrying the Tyr231X mutation that has no residual activity cannot 
be clinically distinguished from those with mutation Glu285Ala that has some residual 
enzyme activity. Patients homozygous for the most common mutation Ala305Glu, with 
no residual enzyme activity, have a clinical course similar to patients with the two Jewish 
mutations (Matalon, 1997). A patient heterozygous for mutations Glyl23Glu, and 
Ala305Glu was phenotypically a severe Canavan patient in spite of being a double 
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heterozygote with residual aspartoacylase activity of 26.9% (Matalon, 1997). 
Interestingly, life expectancy is variable in patients with Canavan disease with the same 
genotype (Matalon and Michals-Matalon, 1999) . Since aspartoacylase has been 
structurally resolved (Le Coq et al., 2006), correlation between the location of disease-
specific mutations and functional protein domains could allow an insight in mutational 
analysis. For example, ATRX mutations cause a broad spectrum of X-linked mental 
retardation syndromes; however, major urogenital abnormalities are associated with 
truncating mutations at the C-terminal part of the protein (Gibbons and Higgs, 2000). 
Again, mutations in the plant homeodomain (PHD)-like domain are associated with more 
severe phenotypes than mutations in the helicase domain (Badens et al., 2006). If the 
disease-causing mutations are mapped onto functional substructures of proteins, a clearer 
picture of genotype-phenotype correlations may emerge. 
Studies reported cellular localization of aspartoacylase in the white matter of the 
corpus callosum and cerebellum along with the thalamus (Klugmann et al., 2005). 
Another  study showed that the staining was more intense in large white matter bundles 
(e.g., corpus callosum, anterior commissure, optic chiasma, corticospinal tract) where 
oligodendroglia are known to be present in greater density than in grey matter regions 
(Kirmani et al., 2002). Aspartoacylase was detected by immunohistochemistry in 
oligodendrocytes and non-reactive microglia but not neurons (Madhavarao et al., 2004). 
Neurons were largely unstained in the forebrain, although a few large reticular and motor 
neurons and many ascending and descending neuronal fibers were moderately stained in 
the brainstem and spinal cord. Most of the staining was confined to the cell body and 
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proximal processes of oligodendrocytes (Klugmann et al., 2005). Co-localization studies 
with labeled lectins indicated that aspartoacylase is also present in microglial cells 
(Madhavarao et al., 2004). Studies showing aspartoacylase activity restricted to the 
cytoplasm (Kirmani et al., 2002; Klugmann et al., 2003) and the nucleus (Hershfield et 
al., 2006) have implied a specific subcellular localization, but this remains to be 
established definitively.  
Characterization of the substrate: N acetyl aspartic acid (NAA) 
NAA is an abundant [5–10mM] amino acid derivative in the vertebrate CNS with 
a molecular mass of 175.1 Da. Most neuropsychiatric disorders like schizophrenia show a 
decrease in NAA levels (Mondino M, 2013), however CD is one of the few diseases 
along with sickle cell disease (Steen RG, 2005) that show high levels. It averages 5.7 
µmol/g of brain in eight mammalian species with a range of 1.6-10.08 µmol/g (Birken 
and Oldendorf, 1989). NAA is generally absent from the cerebrospinal fluid (CSF) 
(Tallan et al., 1956) but present in very high amounts in the aneural and avascular lenses 
(Baslow and Yamada, 1997). Absence of functional aspartoacylase creates a pool of 
NAA in the brain and also results in NAA aciduria. NAAduria is a reliable and specific 
biochemical index for CD (Matalon et al., 1988). Additionally CD patients show very 
high amounts of NAA in their blood and CSF (Matalon et al., 1988).  
NAA serves as a marker of neuronal integrity as high levels indicate brain injury 
and disease; however, the biological function of NAA remains enigmatic. It is 
metabolically compartmentalized; being exclusively produced in neuronal mitochondria 
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by L-aspartate N-acetyltransferase (Asp-NAT) [EC 2.3.1.17] (Ariyannur et al., 2010); 
and metabolized in oligodendrocytes (Madhavarao et al., 2003) by aspartoacylase.  
Animal Models 
Several animal models have been reported showing symptoms similar to CD 
notably foxes (Hagen and Bjerkas, 1990; Hagen et al., 1990), goats (Obermaier et al., 
1995) dogs (Kleiter et al., 2011; Zachary and O'Brien, 1985) and a naturally occurring 
mouse (Azzam et al., 1984); however aspartoacylase activity in the latter was not studied. 
Studies on Canavan disease were initially performed on two rodent models - the naturally 
existing Tremor rat (Kitada et al., 2000) and an artificially engineered Canavan Mouse 
(Matalon et al., 2000). 
The tremor rat is a naturally occurring mutant isolated from an inbred 
Kyoto:Wistar colony that has a large deletion (200kb) spanning 4 genes including the 
aspartoacylase gene, exhibits absence-like seizures and shows spongiform degeneration 
in the CNS (Kitada et al., 2000). Matalon et al genetically engineered a mouse model 
(ASPAKO or CD mouse) that had a specific 10bp deletion in exon IV of the 
aspartoacylase gene (Matalon et al., 2000). Additionally, the phenotype and biochemical 
characteristics of the homozygous knock-out mice indicate that it is a stringent preclinical 
model for evaluating gene therapy for congenital CD and for studying the role of NAA 
and aspartoacylase in the brain. 
Newer studies have created two interesting models one with a single point 
mutation in Nur7 (Traka et al., 2008) and the other - a knock in model (Mersmann et al., 
2011) making development of therapeutic modalities much easier. The Nur7 mouse 
8 
 
model shows spongy neurodegeneration, vacuolization and NAA accumulation like 
patients however myelin rich regions in the brain appear normal (Traka et al., 2008). 
LacZ knock-in mice have a targeted deletion in aspartoacylase and have a mild 
phenotype (Mersmann et al., 2011). These mice are not severely affected and have a 
longer lifespan than the CD mice and could serve as a model for the infantile form of CD 
(Mersmann et al., 2011). 
Theories behind the Molecular Etiology of CD 
A comprehensive investigation of aspartoacylase regulation in oligodendrocytes is 
essential to understand CD pathogenesis because the specific connection between 
aspartoacylase deficiency and the failure of proper CNS development and myelination 
remains unclear. Listed here are existing hypotheses that attempt to offer an explanation. 
Molecular Water Pump and Osmolyte Imbalance Theory 
The adult brain is a major source of metabolic water and uses ~20% of the daily 
caloric intake. Additionally, the two major CD symptoms- increased CSF pressure and 
intramyelinic edema, being hallmarks of profound fluid imbalance, suggest the existence 
of an efficient Molecular Water Pump (MWP) (Baslow, 1999). 
The theory propounds that NAA accumulation could result in osmolytic 
imbalance in the brain since it is similar to taurine (Taylor DL, 1995), an important CNS 
osmolyte. Furthermore, NAA has two juxtaposed anabolic (neurons) and catabolic 
(oligodendrocytes) compartments that suggest a mechanical framework for a MWP in the 
brain. The MWP involves the synthesis and facilitated diffusion of a hydrated 
intracellular osmolyte [NAA with its ion-dipole and dipole-dipole associated water] down 
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its gradient. At maturity, intraneuronal NAA concentration is ∼10±14mM while the 
interstitial concentration is only 80-100µm (Sager TN, 1997), indicating a large outward-
directed transport gradient. The osmolyte [NAA] is rapidly hydrolyzed [by 
aspartoacylase to form aspartate and acetate] to maintain tissue-ECF osmotic balance [in 
the periaxonal space]. The metabolic products are dehydrated as they are once again 
taken up by an active transport mechanism to complete the cycle (Baslow, 1999).  
Presumably, the acetate is taken up by astroglial processes at axon internodes and 
synapses (Tsacopoulos M, 1996) recycling the hydrolyzed products to produce more 
NAA [Figure 1.1]. 
Paranodal seals that connect oligodendrocytes to axons could serve as the site for 
the NAA inter-compartmental bidirectional cycle (Baslow, 1999). Aspartoacylase 
deficiency would lead to accumulation of NAA and water and resulting in an increased 
hydrostatic pressure. This could loosen the tight junctional seals separating interlamellar 
spaces from the extracellular periaxonal and parenchymatous spaces resulting in 
intramyelinic edema (Hirano, 1981). Subsequent demyelination could create vacant 
spaces within the white matter leading to the spongy brain phenotype.  
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Figure 1.1 Molecular Water Pump Theory. NAA is synthesized within neurons by the 
Aspartate-N-Acetyl Transferase (AspNAT) creating a large concentration gradient with 
the interstitial space. NAA and associated dipole water accumulate therein. Under normal 
conditions, aspartoacylase metabolizes the NAA and removes it. Absence of 
aspartoacylase results in accumulation of NAA and its associated water causing 
intramyelinic edema. 
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Figure 1.1 Molecular Water Pump Theory.  
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Dysmyelination Theory 
NAA-derived acetyl groups were shown to be involved in fatty acid synthesis as 
acetyl-labeled NAA injection into rats resulted in maximum fatty acid incorporation just 
before and during myelination (D'Adamo AF Jr, 1968). Later studies indicated that NAA 
was transferred from the axon to myelin and NAA-derived acetate was incorporated into 
myelin lipids (Chakraborty et al., 2001). 
This theory proposes that deficiency of NAA-derived acetate decreases the synthesis of 
myelin-associated lipids in CD leading to dysmyelination (Madhavarao et al., 2005) 
[Figure 1.2]. Additionally, temporal correlations have been shown between 
developmental increases in aspartoacylase activity and myelination (Bhakoo et al., 2001). 
Similar to human CD patients, brain acetate levels are reduced by ∼80% in CD mice 
during peak postnatal myelination while myelin lipids such as cerebrosides and sulfatides 
are reduced (Ahmed SS, 2013; Madhavarao et al., 2005). These data speculate that NAA-
derived acetate is essential during postnatal myelination to supply substrate for some 
proportion of the lipids that make up myelin sheaths in the developing brain. 
Studies on the Nur7 KO mouse (Traka et al., 2008) suggest that spongy 
degeneration is not dependent on disrupted myelin synthesis. Even though Nur7 mice are 
heterozygous for a null allele of a galacto-lipid synthesizing enzyme which could further 
reduce brain cerebroside content, they do not show more severe myelin pathology 
implicating additional mechanisms in the pathophysiology of CD (Madhavarao et al., 
2009). Animal models lacking functional aspartoacylase show abundant albeit  
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Figure 1.2 Dysmyelination Theory. Under normal conditions, aspartoacylase 
metabolizes NAA to provide acetate for myelin synthesis. Deficiency of aspartoacylase 
causes inadequate myelin synthesis leaving gaps in the interstitium where normal sheaths 
would have existed causing vacuolation. 
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Figure 1.2 Dysmyelination Theory.  
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structurally abnormal myelination probably because the initial stages of myelinogenesis 
have redundant pathways (Wang et al., 2009). 
Compromised Epigenetic Regulation of Oligodendrocyte Differentiation 
Studies on oligodendrocyte maturation have highlighted the importance of 
epigenetic control in differentiation (Copray S, 2009). Acetate is derived from NAA in 
oligodendrocytes (Chakraborty et al., 2001) and this acetate is probably important  for 
histone acetylation reactions that regulate chromatin structure and gene transcription. 
Dramatic reduction of acetate resulting from aspartoacylase deficiency could impact 
histone reactions required for epigenetic gene regulation preventing normal 
differentiation leading to oligodendrocyte cell death and neuronal injury possibly 
contributing to vacuole formation.  
Protein Misfolding Theory 
Cells like oligodendrocytes, which have active protein secretory pathways, are 
sensitive to disorders of protein misfolding. Acetyl CoA is an important substrate for 
acetylation and deacetylation of nascent polypeptide chains in the endoplasmic reticulum 
[ER] required for stabilization and correct folding of proteins (Spange S, 2009). Reduced 
acetyl CoA availability due to aspartoacylase deficiency could negatively impact protein 
folding and stabilization, targeting proteins for degradation. Oligodendrocytes are highly 
susceptible to ER stress associated with disruptions in protein synthesis and trafficking 
(Lin W, 2009). In the CD mouse, a severe loss of myelin basic protein and PLP/DM20 
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proteolipid proteins has been observed combined with a decrease in myelinated fibers 
(Kumar et al., 2009).   
Oxidative Stress Theory  
Intracerebroventricular administration of NAA induces seizures in normal rats, 
probably by neuronal overexcitation (Akimitsu T, 2000); further, tardive dyskinesia 
patients also have significantly higher CSF concentrations of NAA like CD patients (Tsai 
G, 1998). Animal studies show that epileptic seizures result in free radical production and 
oxidative damage to cellular proteins, lipids and DNA (Bruce AJ, 1995) implicating 
oxidative stress as one of the possible causes of neurological impairment. Recent work 
suggests that chronic mitochondrial oxidative stress and resultant dysfunction can render 
the brain more susceptible to epileptic seizures (Patel, 2004). Hence it seems that there is 
a role for oxidative stress both as a cause and a consequence of epileptic seizures. 
NAA may promote oxidative stress by reducing non-enzymatic antioxidant 
defenses and stimulating oxidative damage to both lipids and proteins by enhancing 
reactive species in cerebral cortex [Figure 1.3]. In a study, NAA was found to inhibit the 
functions of catalase and glutathione peroxidase (GPX) indicating impaired 
detoxification of hydrogen peroxide but it had no effect on superoxide dismutase [SOD]. 
Acute administration of NAA also enhanced levels of hydrogen peroxide in vitro which 
could possibly be involved in the progression of the characteristic neurodegeneration in 
CD (Pederzolli CD, 2007). Though these results could not be extrapolated to humans, 
they do reveal probable mechanisms since the oxidative stress parameters occurred with 
concentrations of NAA  (∼4fold higher) observed in plasma and CSF of patients affected 
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by CD (Tsai and Coyle., 1995). Based on the supposition that NAA may promote 
oxidative stress in vitro and in vivo both by enhancing reactive species and diminishing 
antioxidant defenses, administration of antioxidants, especially vitamins E and C, could 
be considered as a potential adjuvant therapy for patients affected by CD (Pederzolli CD, 
2007). 
A previous study linked NAA accumulation to nitric oxide [NO] toxicity as it 
upregulates inducible nitric oxide synthase [iNOS] and stimulates neuronal and 
endothelial nitric oxide synthase (Surendran, 2009). Increased NO levels lead to 
disturbances in DNA structure and enhance protein interaction (Lee DH, 2007). 
Discrepancies in the molecular weight of aspartoacylase when prepared using different 
methods (Kaul et al., 1993) suggest that it may dimerize based on its concentration. It is 
possible that upregulation of NO synthase as a direct result of NAA accumulation may 
nitrosylate aspartoacylase causing it to dimerize. This hypothesis proposes that NAA 
upregulation and aspartoacylase malfunction could be cyclically linked. 
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Figure 1.3 Oxidative Stress Theory. Accumulation of NAA in the interstitium due to 
the absence of aspartoacylase gives rise to Reactive Oxygen Species (ROS) that cause 
inflammation and result in vacuolation and degeneration of white matter. 
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Figure 1.3 Oxidative Stress Theory.  
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Palliative Measures: Past and present 
CD was described as one of the few neurological diseases which manifests 
increased NAA levels in the brain; most other neurological diseases like schizophrenia 
show low NAA levels (Mondino M, 2013). Since an increasing number of substances can 
affect NAA levels in the brain (Baslow and Resnik, 1997); slowing down the anabolic 
portion of the NAA cycle using pharmaceuticals  may allow the existing, albeit enzyme-
deficient oligodendrocytes to produce a stable myelin sheath and restore neurological 
function.  
A large number of preclinical proof-of-concept studies have been performed on 
various CD animal models (described above) making development of therapeutic 
modalities much easier. Though currently the patients are mostly supported by palliative 
measures; existing treatment modes focus on different aspects of the disease phenotypes 
and are described below. 
Managing symptoms in the clinic 
Most of the palliative measures for patients of Canavan’s disease follow the care 
provided for patients of other pediatric neurodegenerative diseases (Hunt and Burne, 
1995). Current palliative measures for Canavan patients with respiratory issues include 
suction and cough assist machines to clear secretions and mucous from the  mouth, 
throat, nose and upper lobes of the lungs; the Vesta system for airway clearance and 
oxygen concentrators to provide a continuous flow of oxygen for easy breathing.  
Hypotonia being a major Canavan symptom requires positioning equipment 
which may include foam supports, feeder seats, specialized strollers and bath chairs to 
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help patients with their positioning needs. Feeding pumps are also used to assist in 
dispensing liquid nutrients at predetermined rates for feeding. Nebulizers help to 
administer medication as aerosols for these patients. 
Symptomatic treatment of disease 
The earliest human clinical trials on CD patients used acetazolamide to reduce 
water concentration and NAA levels in white matter for a period of 5 months. The drug 
reduced intracranial pressure, but did not reduce water content or NAA levels (O. Bluml, 
1998). A ketogenic diet increased levels of β-hydroxybutyrate in the brain but did not 
affect the elevated levels of NAA (Novotny EJ Jr, 1999). These treatment strategies were 
primarily targeted to alleviate edema; however there was little to no benefit for the 
patients.  
In recent years, intraperitoneal injections of lipoic acid (that can cross the blood 
brain barrier,BBB  (Samuel S, 2005)) have also been tried in preclinical studies using 
tremor rats, the naturally occurring animal model for CD (Pederzolli CD, 2007) based on 
the fact that NAA induces oxidative stress in the CNS. The encouraging results suggest 
that this might be a good therapeutic approach for symptomatic treatment.  
Addressing the Missing Metabolite by Dietary Supplementation 
Dietary supplementation of acetate in newborn patients was proposed as a 
therapeutic for CD since the primary pathogenesis is postnatal and deficiency of 
aspartoacylase and acetate are concurrent (Madhavarao et al., 2009). This group reported 
phenotypic improvements in myelin galactocerebroside content and brain vacuolation 
and also showed a partial reversion in motor dysfunction in GTA-treated tremor rats over 
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a course of 4 months (Madhavarao et al., 2009). In conclusion, dietary supplementation 
may not totally alleviate an inherent genetic metabolic disorder but definitely offers 
partial symptomatic alleviation. Clinical translation of GTA to human infants showed no 
significant side effects or toxicity but showed no motor improvement (Segel R, 2011). 
A recent study proposed dietary triheptanoin supplementation in Nur7 mice to 
support fatty acid synthesis and TCA cycles and improve the redox status in diseased 
animals. It showed phenotypic improvements suggesting that the underlying pathological 
mechanism of CD may be a combination of several factors (Francis et al., 2013). 
Addressing the Elevated Substrate by Neuroprotective Strategies 
Neuroprotective strategies may be needed to counteract neurological damage 
caused by oxidative stress possibly by the accumulated NAA. Intra-peritoneal lithium 
administration caused a significant drop in brain NAA levels in wild type rats (O'Donnell 
T, 2000) and tremor rats (Baslow et al., 2002). After 1 year of treatment in patients, NAA 
levels in both urine and brain were decreased. Patients showed improved alertness and 
visual tracking; however axial hypotonia and spastic dysplegia were unaffected (Solsona 
MD, 2012). Pharmacologically, lithium is neuroprotective for dementia patients (Kessing 
LV, 2008) possibly by reducing expression of pro-apoptotic proteins (Chen RW, 1999) 
and increasing the levels of anti-apoptotic proteins (Chang YC, 2009). 
A complete inhibition or even a significant reduction in NAA production may 
thus be a viable option in controlling demyelination and improving the quality of life in 
CD patients.  However solely controlling brain NAA levels for CD (Assadi et al., 2010) 
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may not be a highly effective therapeutic strategy since the NAA system is not 
universally present in neurons (Baslow, 1997). 
Addressing the Enzyme deficiency by Enzyme Replacement 
Using enzyme replacement as a therapeutic for neurological disorders has been 
difficult because of the challenging blood–brain-barrier. Surface lysyl groups of human 
aspartoacylase were modified through PEGylation to decrease immune response and 
increase circulation half-life with the intention of treating CD patients (Zano et al., 2010). 
Most of these modalities as CD therapeutics showed good tolerance but did not 
cause any significant improvement in the quality of life in the patients. However, as CD 
is a monogeneic defect with pathology being most evidently localized in the CNS, it 
presents an attractive target for gene therapy.  
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Gene Therapy for Canavan Disease 
Gene therapy is a promising area of experimental medicine wherein 
supplementation or alteration of DNA is used as a therapeutic in organisms to alleviate a 
genetic disease. The most common approach involves replacement of a non-functional or 
absent gene by an artificial cassette that would restore functionality of the gene. 
Therapeutic DNA is packaged into a "vector" that delivers DNA in cells after which the 
cellular machinery takes over and produces the deficient protein to correct the disease. 
Non Viral Gene therapy  
Non-viral gene delivery system is a conventional approach for gene therapy; 
however it is limited by efficiency of gene transfer. Direct injections of plasmids (naked 
or in complexes) are also inefficient because of limited uptake due to aggregate 
formation, low rates of diffusion, endotoxin contamination and transient expression 
necessitating improvements in design (O'Mahony et al., 2013). Therefore, there are 
ongoing efforts to achieve safe, efficient and specific non-viral vectors which match the 
efficacy of viruses. 
The first clinical trial for CD used a non-viral gene transfer technique with 
intracerebroventricular injections of a non-aggregating lipid plasmid formulation LPD. 
This was composed of a recombinant plasmid with a condensing agent [poly-L-lysine or 
protamine sulfate] and a liposomal formulation [DC-CHOL/DOPE] on two Canavan 
patients (Leone et al., 2000). The study established that the gene transfer technique 
worked and was safe but differences in the responses of the patients made it difficult to 
conclude if the gene therapy was successful.  
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Viral Gene therapy  
Viral vectors have been widely used as gene delivery systems as they can 
introduce their genetic material into recipient cells. Desired properties of a viral vector 
include replication deficiency, non-immunogenicity, non-toxicity and the ability to 
deliver its genetic material to the nucleus of a target cell (Ruitenberg et al., 2002). Gene 
therapy viral vectors mediating specific delivery into the CNS range in capacity from 
4.5kb to 150kb (Davidson and Breakefield, 2003).  
Preclinical viral gene therapy studies involved stereotactical adenovirus-mediated 
delivery of aspartoacylase in tremor rats that showed reduction of seizures (Seki et al., 
2002) and AAV2 mediated delivery that showed significant improvement in motor 
abilities and elevation of aspartoacylase expression (McPhee et al., 2005). 
One of the more popular viral vector choices for CD gene therapy is the Adeno 
associated virus (AAV) that is described in more detail in the next section. 
Adeno-Associated Virus (AAV) 
Adeno-associated virus (AAV) is one of the smallest nonpathogenic mammalian 
viruses discovered as a contaminant of adenovirus culture resulting in its name (Mayor et 
al., 1965). It belongs to the family Parvoviridae in the genus Dependovirus (as it depends 
on a helper virus e.g. adenovirus for replication) (Daya and Berns, 2008). 
Structure  
The wildtype virus is a 4.7kb non-enveloped single stranded DNA (ssDNA) virus 
reported to be 25nm in diameter with a molecular weight of 1.4x106 Da. It is 
characterized by 2 open reading frames (ORFs) coding for a total of 7 viral proteins 
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important for replication and capsid production respectively. The left ORF encodes 4 Rep 
proteins Rep78, Rep68, Rep52 and Rep40 produced as unspliced and spliced transcripts 
using the P5 and P19 promoters respectively. They are regulatory proteins that are 
important in production of single stranded viral DNA for packaging. The right ORF 
encodes three viral capsid proteins from the P40 promoter namely VP1 (87kD), VP2 
(72kD) and VP3 (62kD). 60 viral capsid proteins are produced in a defined ratio that has 
been variously described as 1:1:10 (Vandenberghe et al., 2009) and 1:1:18 (Opie et al., 
2003) to form an icosahedral structure. The 2 ORFs are flanked by 145bp inverted 
terminal repeats (ITRs) where the first 125 nucleotides being palindromic can fold on 
themselves to form a T-shaped hairpin. The unpaired 20 bases constitute the D sequence 
(Wang et al., 1997).  The hairpin helps in DNA replication in the presence of a helper 
virus by serving as a primer for second strand synthesis. The ITRs also contain Rep 
binding elements and a terminal resolution site that are critical for AAV replication. 
Additionally, ITRs are essential for AAV genome packaging, transcription, negative 
regulation under nonpermissive conditions and site-specific integration (Daya and Berns, 
2008). 
There are several rate determining factors that contribute to efficiency of 
transduction including entry into the nucleus and uncoating of DNA from the capsid 
(Sipo et al., 2007; Thomas et al., 2004). However, the most important rate limiting step 
involves conversion of the single-strand DNA (ssDNA) vector genome into double-
stranded DNA (dsDNA) prior to gene expression (Ferrari et al., 1996; Fisher et al., 1996).  
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This critical step can be entirely circumvented by packaging both strands as a single 
molecule through the use of self-complementary AAV (scAAV) vectors [Figure 1.4]. 
scAAV vectors can be packaged like conventional AAV genomes, when the two 
halves of the ssDNA molecule fold and base pair to form a molecule of half the length 
(McCarty et al., 2003). In order to enhance vector transduction efficiency and accelerate 
gene expression, the terminal resolution site (trs) from one end was deleted thus 
preventing the initiation of replication. These constructs generated single-stranded, 
inverted repeat genomes, with a wt TR at each end, and a mutated TR in the middle. 
After uncoating, the viral DNA folds through intramolecular base pairing within the 
mutant TR, which then proceeds through the genome to form a double-stranded 
molecule. As conversion from single to double strand does not depend on vector 
concentration or host cell assisted DNA replication, scAAV vectors result in efficient and 
fast transgene expression even though this measure further restricts the transgene size in 
an already small vector.  
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Figure 1.4 Advantages of self complementary rAAVs over single stranded AAVs. 
ssAAVs show delayed expression since they require intermolecular hybridization as 
either a plus or a minus strand is packaged into a capsid. scAAVs on the other hand 
require intramolecular hybridization that speeds up the time of gene expression. 
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Figure 1.4 Advantages of self complementary rAAVs over single stranded AAVs.  
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Preclinical Applications 
 AAVs are almost completely nontoxic after CNS delivery in non-preexposed 
mammals (Afione et al., 1995; Samulski RJ, 1999) and have sustained gene expression in 
non-dividing cells (Samulski RJ, 1999). Recombinant AAVs are gutted versions that do 
not contain any coding sequences from the naturally occurring viruses but carry a 
complete transcription cassette with the gene of interest flanked by ITRs. rAAVs are a 
preferred vector of choice for a lot of CNS gene therapy applications as they mediate 
persistent and safe  neuronal transduction (Kaplitt et al., 1994). Such CNS transduction is 
quite consistent through several species of mammals like mice, cats, dogs and monkeys 
(Asokan et al., 2012; Cotugno et al., 2011; Foust et al., 2010; Gagliardi and Bunnell, 
2009; Gray et al., 2011). Clinical trials using rAAV are ongoing for different neurological 
diseases (Asokan et al., 2012), and available data suggests that these vectors are capable 
of mediating long-term stable gene expression in the human brain as well (Hwu et al., 
2012; Muramatsu et al., 2010). 
AAV2 was the first serotype to be successfully used for gene transfer (Hermonat 
PL, 1984); however, it is has limited applications in CNS directed therapy since the brain 
is refractory to systemic delivery of rAAV2. This is due to the presence of the BBB 
(which physically excludes foreign molecules and microorganisms based on size, charge, 
and lipid solubility from the blood to the brain) efficiently blocking rAAV entry into the 
CNS (Zlokovic, 2008) and rendering it incapable of marked therapeutic benefit for global 
neurological disorders like CD which have no cure to date. 
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Need for Different Serotypes 
AAV2 vectors sparked a widespread interest in the gene therapy field since they 
were able to effect a persistent transgene expression, apparent lack of pathogenicity and 
an affinity for multiple organs like the liver (Snyder et al., 1997), eye (Guy et al., 1999), 
intestine (During et al., 1998) and muscle (Pruchnic et al., 2000). Recombinant AAV2 
vectors have been used therapeutically in preclinical studies for a wide variety of diseases 
(Flotte et al., 1993; Gasmi et al., 2007) and several clinical trials with hundreds of 
patients have been completed or initiated (Mingozzi and High, 2011). Although the safety 
and efficacy of AAV2 vectors for in vivo gene transfer have been widely acclaimed, 
research suggests that the transduction efficiency of AAV2 vectors in organ-specific 
transgene expression leaves a lot to be desired (Nakai et al., 2002; Zabner et al., 2000). 
Another important consideration is the negative effect of neutralizing antibodies in the 
serum on AAV transduction efficiency (Janelidze et al., 2014). This alone would 
jeopardize any application requiring repetitive therapeutic administration. Moreover, 
since the transduction efficiency of AAV is substantially dependent on capsid structure, it 
generated a widespread interest in the identification, characterization and isolation of 
additional AAV capsids. A lot of research is also focused on modifying vector genomes 
as well as capsid proteins to improve the transduction efficiency of AAV2-based vectors.  
AAV capsid determines biodistribution and transduction efficiency in addition to 
being the focal point of contact between the therapeutic gene and the host (Grimm and 
Kay, 2003; Grimm et al., 2006). Research has indicated that hybrid vectors generated by 
cross packaging the genetic backbone of AAV2 with the capsid component of other AAV 
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serotypes are more efficient than the natural variants in transducing organs and tissues 
suggesting the need for studying serotype-specific vector distribution (Rabinowitz et al., 
2002). A case in point is that AAV4 and 5 target ependymal cells in the CNS at a higher 
efficiency compared to AAV2 (Davidson and Breakefield, 2003; Davidson et al., 2000). 
Capsids presumably also affect the interactions of AAVs with anatomical barriers like the 
BBB (Vandenberghe et al., 2009).  
Need for a therapeutic time window 
An important issue would be to determine how far along in disease progression 
can the treatment be administered to patients to achieve substantial therapeutic benefits. 
Neurometabolic diseases like globoid cell leukodystrophy show favorable outcomes for 
presymptomatic intervention but not later indicating the existence of a restricted 
therapeutic time window (Escolar ML, 2005). Similar outcomes were seen in preclinical 
studies (Ahmed SS, 2013) and follow up study on CD clinical trials (Leone et al., 2012) 
indicating that future gene therapy interventions should begin before irreversible neuro-
structural changes occur underlining importance of rodent studies. 
Looking ahead 
It has been more than 8 decades since CD was first described in 1931 (Canavan, 
1931) and there was little progress in understanding its pathogenesis until it was 
identified as an aspartoacylase deficiency almost 5 decades later (Matalon et al., 1988). 
Description of the human aspartoacylase cDNA sequence led to a huge leap in molecular 
diagnosis for CD patients (Kaul et al., 1993); however, the molecular etiology has 
remained controversial. To resolve this, strong efforts in modeling CD in animals 
33 
 
significantly broadened avenues to investigate pathological mechanisms. Preclinical 
studies began with the naturally existing tremor rats and then expanded to include the CD 
mouse and later the Nur7 and the LacZ knock-in mouse models.  
Discovery of rAAV serotypes that can cross the BBB revolutionized the field 
(Foust et al., 2009; Yang et al., 2014; Zhang et al., 2011); however, an important issue in 
translation of the intravenous rAAV therapeutic dose from mice to humans is the huge 
vector manufacturing burden, making treatment costs prohibitive. Codon optimization of 
the expression cassette would increase expression efficiency and lower therapeutic doses. 
Moreover delivery of vector to the CSF directly would enhance diffusion in the CNS and 
lesser spread in peripheral organs. Again surprisingly the kidney expresses high levels of 
aspartoacylasebut has low NAA levels suggesting additional catalytic functions for 
aspartoacylase. Thus, alternate approaches may be needed to deal with the pathological 
consequences of loss in aspartoacylase activity in such peripheral tissues. 
Long term studies on rAAV gene therapy- treated patients have documented that 
it is safe and risk-free. CD is a monogenic genetic disorder with very distinct core clinical 
features that is amenable for gene therapy. Inclusion of newer CD animal models, 
continuously expanding viral vector repertoire and less invasive delivery methods for 
pan-CNS delivery make it likely that gene therapy for CD and other such diseases will 
advance rapidly in the near future. Efficient translation of the comprehensive data-driven 
validation of effective therapy in mouse models to humans would push forward the 
successful development of therapeutics like rAAVs and provide a viable treatment for 
patients who previously had none.  
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Focus of this dissertation 
This dissertation focuses on developing an efficacious gene therapy for Canavan disease 
using recombinant AAVs in the aspartoacylase knockout mouse model in a preclinical 
setting. In Chapter 2, we characterize novel variants of AAVs that can cross the blood 
brain barrier becoming effective tools for treatment of neurological disorders. An 
intravascular delivery of these vectors also targets peripheral tissues to cause potential 
detrimental effects; hence we also describe construction of tissue-specific, endogenous 
microRNAs (miRNAs) to repress rAAV expression outside the CNS, by engineering 
perfectly complementary miRNA-binding sites into the rAAV9 genome. In Chapter 3, we 
show that a single intravenous injection of 3 AAV variants can ameliorate disease 
symptoms in a bona fide mouse model. We also for the first time document that 
microRNAs can be used to restrict transgene expression in the CNS using AAVs as 
vectors. Additionally, we define a therapeutic time window for delivery of vectors in CD 
showing that vector administration as late as P20 can rescue lethality in the animal 
model. In Chapter 4, we further try to increase efficiency by intracerebroventricular 
delivery of rAAVs to minimize systemic viral load, potential systemic toxicity, off target 
expression and lower vector manufacturing burden yet achieve widespread transgene 
expression. We extensively describe peripheral pathology in the animal model and report 
for the first time that the immune system may be severely compromised in CD. We also 
shed light on the role of neural cell types on the disease pathophysiology. 
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CHAPTER II: CHARACTERIZATION OF AAV VARIANTS THAT CAUSE 
WIDESPREAD CNS TRANSDUCTION FOLLOWING INTRAVENOUS 
DELIVERY 
The following chapter contains parts of the manuscripts 
Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, 
Brown R, Xu Z, Gao G. (2011). Several rAAV vectors efficiently cross the blood-brain 
barrier and transduce neurons and astrocytes in the neonatal mouse central nervous 
system. Molecular Therapy Aug; 19(8):1440-8 [PMID: 21610699]. 
 
Yang B, Li S, Wang H, Guo Y, Gessler DJ, Cao C, Su Q, Kramer J, Zhong L, Ahmed SS, 
Zhang H, He R, Desrosiers RC, Brown R, Xu Z, Gao G. (2014) Global CNS transduction 
of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman 
primates by rAAVrh.10. Molecular Therapy Jul; 22(7):1299-309. [PMID: 24781136] 
 
The studies were a large part of my rotation project and I was involved in perfusing, 
embedding, sectioning of the mice used. All the staining for mouse tissues was done on 
these sections. 
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CHAPTER II: Characterization of AAV variants that cause widespread CNS 
transduction following intravenous delivery 
Introduction 
Monogenic neurodegenerative disorders where gene mutations cause loss of 
function or gain of a deleterious new property/function are ideal candidates for gene 
therapy.  This may be either through the delivery of the normal gene, in the former case, 
or vehicles that can silence a miscreant gene and protein by RNA interference 
(Manfredsson and Mandel, 2010; Urbaniak Hunter et al., 2010). Though targeted vector 
delivery into discrete structures in the central nervous system (CNS) is highly effective 
for diseases with a localized lesion, or those where localized transgene expression is 
sufficient to alleviate disease phenotype (Cearley et al., 2008), it comes at a cost of 
surgical risks and clinical costs. Moreover such an approach is not suitable for global 
CNS diseases that require more dispersed transduction. 
Among non viral and viral vectors, recombinant adeno-associated viruses 
(rAAVs) have demonstrated a great potential in CNS gene transfer (Davidson and 
Breakefield, 2003).  In human clinical trials, direct injection of AAV vectors gave rise to 
sustained transgene expression and therapeutic effect (Kaplitt et al., 2007). Emerging 
self-complementary AAV (scAAV) vectors hold extra advantages over their single strand 
counterparts due to higher gene delivery efficiency (McCarty, 2008). 
An ideal approach to address widespread CNS disorders would harness the 
vasculature since the brain is a highly vascularized organ. A critical impediment to 
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widespread CNS gene transfer via the vasculature is the blood–brain barrier (BBB), 
which is a complex anatomical barrier including endothelial tight junctions, astrocytic 
end-feet, pericytes, and cellular basement membrane (Bradbury, 1985). The barrier 
precludes the entry of >98% of small molecule and almost all macromolecules including 
therapeutic proteins and gene delivery vectors into the CNS (Pardridge, 2002).  
In order to overcome the restricted entry of viral particles into the CNS and low 
transduction efficiency, discovery of new clades of novel primate AAVs with unique 
tissue/cell tropisms and varying efficiencies of in vivo gene transfer is important (Gao et 
al., 2004; Gao et al., 2002). One of these novel primate serotypes, rAAV9, can achieve 
robust transduction of neuronal and glial cell types in the CNS of murine neonates 
following intravenous injections (Foust et al., 2009) and has shown encouraging results in 
treating a number of CNS diseases that require early life intervention (Falk et al., 2013; 
Hinderer et al., 2014; Jiang et al., 2006).This is an important breakthrough in CNS gene 
therapy, although the host-serological response to AAV9 may preclude its widespread 
use.  
There are however other challenges to rAAV-mediated systemic gene delivery to 
the CNS. The first challenge is to deliver rAAV specifically to the CNS. The viral capsid 
is the principal determinant for AAV tissue tropism (Vandenberghe et al., 2009), and the 
liver is the major target for AAV vectors (Nakai et al., 2005). Systemic administration of 
some rAAV serotypes transduces the liver and other tissues, including the CNS, skeletal 
muscle and heart (Wang et al., 2005; Zincarelli et al., 2008). Such off-target transduction 
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raises the spectre of overexpression of transgenes outside the CNS, potentially eliciting 
toxic responses. The other challenge is to confine transgene expression to the CNS. 
Historically, CNS-specific promoters have been used for this purpose; however, tissue-
specific, strong CNS promoters like the neuron-specific enolase (NSE) and neuron-
specific human platelet-derived growth factor-β (PDGF-β) chain are too large to be 
packaged into the rAAV genome (Hioki et al., 2007). 
We first report a survey of nine scAAV vectors for their CNS gene transfer 
properties after systemic administration in neonatal mice using rAAV9 as a control. We 
investigated enhanced permeation of the BBB and improved delivery of enhanced green 
fluorescent protein (EGFP) to the CNS following facial vein injection on P1. Our data 
document that the ability to cross the BBB in neonatal mice is not restricted to rAAV9. 
We then characterized highly CNS tropic rAAV(s) with naturally reduced peripheral 
tissue tropism for systemic gene delivery to the CNS in adult animals. We compared the 
CNS transduction efficiencies of 12 different rAAVs (rAAV 1, 2, 5, 6, 6.2, 7, 8, 9, rh.8, 
rh.10, rh.39, and rh.43) in 10-week-old mice following systemic delivery.  
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Material and Methods 
Vector design and construction: The EGFP reporter vector genome uses a hybrid 
cytomegalovirus enhancer/CB promoter cassette; AAV2 inverted terminal repeats, rabbit 
beta globin intron, eGFP cDNA and a rabbit globin poly A. The miRNA-regulated EGFP 
construct was created by inserting three copies each of miR-1 and miR-122 target sites in 
tandem in the 3′ UTR of EGFP reporter gene as previously described (Xie et al., 2012).  
AAV production: All scAAV vectors were produced by trans-encapsidation of rAAV 
vector genome flanking by inverted terminal repeats from AAV2 with the capsids of 
different AAVs using the method transient transfection of 293 cells and CsCl gradient 
sedimentation as described previously (Sun et al., 2010). Vector preparations were titred 
by quantitative PCR. Purity of vectors was assessed by 4–12% SDS-acrylamide gel 
electrophoresis and silver staining (Invitrogen, Carlsbad, CA). Morphological integrity of 
each vector used in the study was examined by transmission electron microscopy of 
negative stained recombinant AAV virions at Electronic Microscopy Core, University of 
Massachusetts Medical School, Worcester, MA.  
Animal procedures: All animal procedures were approved by the Institutional Animal 
Care and Use Committees of University of Massachusetts Medical School.  
For neonatal injections, wild-type C57BL/6 mice littermates were used. Breeding 
were conducted using programmatic timing. Pregnant mice were monitored daily from 
embryonic day 17 to 21 to ensure the newborn pups could be dosed with vectors on P1. 
Vectors were injected in P1 pups at a concentration of 4 × 1012 genome copies/ml in PBS 
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(Stoica et al., 2013).  Each pup received 4 × 1011 genome copies of different 
scAAVCBEGFP vectors (rAAV1, rAAV2, rAAV5, rAAV6, rAAV6.2, rAAV7, rAAV9, 
rAAVrh.10, rAAVrh.39, rAAVrh.43; n = 6–8 mice per group).  
For adult injections, 10-week-old C57BL/6 mice (n = 3) with an average body weight of 
20 g were treated with rAAV vectors via tail vein injections at a dose of 4 × 1012 
GCs/mouse in 100μl PBS.  
Histological processing: Mice were anesthetized 21 days postinjection and transcardially 
perfused with 15 ml of cold phosphate-buffered saline (PBS) followed by 15 ml of 
fixation solution containing 4% paraformaldehyde (v/v) in PBS. Brain and spinal cord 
were extracted and postfixed in 4% paraformaldehyde overnight (n = 3). The mouse 
tissues were cryoprotected in 30% sucrose (w/v) in PBS, embedded in Tissue-Tek OCT 
compound (Sakura Finetek, Torrance, CA) and frozen in a dry ice/ethanol bath. Serial 40-
μm floating sections of the entire brain as well as 3-mm segments from cervical, thoracic, 
and lumbar regions of the spinal cord were cut with a Cryostat (Thermo Microm HM 
550; Thermo Scientific, Walldorf, Germany). 
Immunohistochemistry: Brain and spinal cord sections were stained as floating sections 
in 12-well plates. Sections were washed three times in PBS for 5 minutes each time, and 
then incubated in blocking solution containing 0.1% Triton-X100 (v/v) (Fisher, Pittsburg, 
PA) and 10% goat serum (v/v) (Invitrogen, Frederick, MD) for 1 hour at room 
temperature. Sections were then incubated with primary antibodies diluted in blocking 
solution at 4 °C overnight. The following day tissue sections were washed twice in 0.05% 
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Tween-20 (v/v) in PBS (PBST) and once with PBS, with each washing step lasting 10 
minutes. Sections were subsequently incubated with appropriate secondary antibodies in 
blocking buffer for 1 hour at room temperature. Sections were washed again as above. 
For fluorescent detection, sections were mounted with Vectashield with 4',6-diamidino-2-
phenylindole (DAPI; Vector Laboratories, Burlingame, CA) and analyzed using an 
epifluorescent microscope (Nikon Eclipse Ti; Nikon Instruments, Melville, NY) or a 
Leica TSC-SP2 AOBS confocal microscope equipped with a ×63 oil lens and a DM-
IRE2 inverted microscope.  
For avidin biotin complex-3,3′-diaminobenzidine detection, sections were incubated in 
0.1% peroxide/PBS and biotin/avidin blocking solution prior to primary antibody 
incubation to quench endogenous peroxidase and biotin activity. After incubation with a 
biotinylated secondary antibody, sections were washed and incubated in ABC reagent 
(PK-6200; VectorLabs) for 30 minutes at room temperature. After a quick wash in PBS, 
sections were developed with DAB solution (SK-4105; VectorLabs) for 60 seconds 
followed by three consecutive washes in PBS lasting 5 minutes each. Sections were 
subsequently dehydrated in a graded ethanol series of 50, 70, 95, and 100%. After two 
changes of xylene, sections were coverslipped with permount mounting media (Fisher) 
and left overnight to dry.  
The primary antibodies used in this study were as follows: anti-APC (OP80, Calbiochem, 
Billerica, MA) rabbit anti-GFP (Invitrogen), goat anti-ChAT and mouse anti-NeuN (both 
from Millipore, Billerica, MA), mouse anti-glial fibrillary acidic protein (Cell Signaling, 
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Danvers, MA), rat anti-CD34, rabbit anti-CD31 (both from Abcam, Cambridge, MA), 
mouse anti-Calbindin D-28k (Sigma, St Louis, MO), and mouse anti-tyrosine 
hydroxylase monoclonal antibody (Millipore). The secondary antibodies used in the 
study included: DyLight 488 AffiniPure Donkey antirabbit IgG; DyLight 549 AffiniPure 
Donkey Anti-Goat IgG; DyLight 549 Affinipure Goat antirat IgG; DyLight 594 
AffiniPure Goat antimouse IgG (all from Jackson ImmunoResearch, West Grove, PA); 
goat antirabbit IgG-Alexa fluro 488 and goat antimouse IgG-Alexa fluro 568 (both from 
Invitrogen). 
Semiquantitative analysis of EGFP-positive cells: To provide a semiquantitative 
measure of the amount and type of cells that were transduced by rAAVs in the CNS, we 
used a previously described scoring system (Cearley et al., 2008). Briefly, the number of 
(+) corresponds to the number of EGFP-positive cells where (+) means very few positive 
cells, (++) some positive cells, (+++) many positive cells, (++++) large areas of positive 
cells, and (+++++) saturated with positive cells. Regions with no EGFP expression are 
marked as (−). Mean scores were calculated by averaging plus signs for all brain and all 
spinal cord areas (n = 3).  
Next, we selected 12 subanatomical, functionally important regions in the brain as well as 
cervical, thoracic, and lumbar sections of the spinal cord for quantitative analysis of 
images that were taken on a Nikon Eclipse Ti inverted microscope equipped with a 
Retiga 2000-RV CCD cooled camera. Nikon NIS elements AR software version 3.2 was 
used for intensity quantification. Prior to quantification, optimal light source intensity and 
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exposure times were obtained by plotting an intensity/exposure time curve using 
fluorescence reference slides (Ted Pella, prod. 2273; Ted Pella, Redding, CA). It was 
found that the intensity and exposure times had linear correlation. In addition, 
overexposure and extreme underexposure distorts the linear correlation. We have 
therefore used the maximum intensity (ND1) and a 20ms exposure for all sections to 
avoid overexposure. For quantification, fixed region of interest was used to quantify the 
brightest area of any given brain region. A mean intensity (total intensity/size of region of 
interest) was obtained for each region of all serotypes. Statistical analysis was performed 
using one-way analysis of variance test for comparison of semiquantitative scores as well 
as biodistribution data.  
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Results 
Intravenous injection of rAAVs mediated widespread transduction in neonatal mouse 
CNS  
We compared the CNS transduction profiles of the following recombinant AAV 
vectors encoding EGFP: rAAV1, rAAV2, rAAV5, rAAV6, rAAV6.2, rAAV7, rAAV9, 
rAAVrh.10, rAAVrh.39, and rhAAVrh.43 21 days post injection in P1 pups. As assessed 
by the scoring system (Cearley et al., 2008), rAAV9 was indeed among the best 
performers; seven out of nine other rAAVs tested (rAAV1, rAAV6, rAAV6.2, rAAV7, 
rAAVrh.10, rAAVrh.39, and rAAVrh.43), but not rAAV2 and rAAV5, also gave rise to 
widespread EGFP expression in the CNS [Table 2.1]. However, the apparent number of 
EGFP-positive cells varied between CNS structures in a vector dependent manner. The 
region with the highest EGFP transduction was the hypothalamus followed by medulla, 
striatum, hippocampus, cortex, and cerebellum. In contrast, the transduction efficiency in 
olfactory bulb and thalamus was relatively low [Table 2.1]. We also assessed average 
EGFP signal intensity/pixel in 12 different CNS regions to derive a more quantitative 
assessment of gene transfer efficiency of each rAAV [Figure 2.1a]. For the eight rAAV 
vectors that achieved CNS transduction after intravenous injection, the mean EGFP 
signal intensity/pixel was relatively low in cortex, habenular nucleus, cornu ammonis, 
dentate gyrus, thalamus, cerebellum, and olfactory bulb, moderate in choroid plexus and 
caudate- putamen, but high in hypothalamus, medulla and amygdala [Figure 2.1a]. Next, 
the average EGFP signal intensity/pixel in the brain (average of 12 regions) for different  
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Table 2.1 Semi Quantitative evaluation of vector performance. Based on the Cearley 
system, we established a scoring system to evaluate efficiency of vector transduction (See 
Materials and Methods).  
Scoring: (−) no transduction, (+) very few positive cells, (++) some positive cells, (+++) 
many positive cells, and (++++) region is almost saturated with EGFP-positive cells. The 
number of animals (n) is given to the right of the score. 
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Table 2.1 Semi Quantitative evaluation of vector performance. 
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Figure 2.1 Quantification of GFP intensity levels in brain and spinal cord. 4 × 1011 
genome copies of ten different rAAV vectors were injected into neonatal P1 pups via the 
superficial temporal vein. Mice were killed 21 days after injection, and 40 μm brain and 
spinal cord cryosections were stained with an anti-EGFP antibody for 
immunofluorescence. (a) EGFP signal intensity/pixel in different brain and spinal cord 
regions was measured for each rAAV vector. (b) Average EGFP signal intensity/pixel in 
brain and spinal cord corresponds to the average value across all respective structures 
analyzed individually in (a). CSP, cervical section of spinal cord; D, dorsal region; 
EGFP, enhanced green fluorescent protein; LSP, lumbar section of spinal cord; rAAV, 
recombinant adeno-associated virus; TSP, thoracic section of spinal cord; V, ventral 
region. 
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Figure 2.1 Quantification of GFP intensity levels in brain and spinal cord.  
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rAAVs were compared [Figure 2.1b]. AAVrh.10, AAVrh.39, and AAVrh.43 stood out 
for their overall gene transduction efficiency in brain, followed by AAV7, AAV9, and 
AAV1 [Figure 2.1b]. 
These eight effective serotypes also mediated EGFP expression throughout the 
spinal cord, to different degrees. The same quantitative analysis was performed for each 
rAAV in the cervical, thoracic and lumbar sections of the spinal cord [Figure 2.1a]; the 
average EGFP signal intensity/pixel of the three sections for different rAAVs were also 
compared [Figure 2.1b]. Overall, rAAV1, rAAV9, rAAVrh.10, rAAVrh.39, and 
rAAVrh.43 displayed stronger transduction in the spinal cord with the highest EGFP 
signal intensity/pixel observed in cervical, followed by thoracic and lumbar sections of 
the spinal cord [Figure 2.1]. For rAAV2 there were only a few EGFP-positive cells in 
hippocampus, cortex, and hypothalamus, while none was observed in most CNS regions 
in AAV5-injected mice except in the hypothalamus.  
The following is a more detailed description of our findings. Selection of CNS 
structures was based on their relevance to neurodegenerative diseases in humans (e.g., 
striatum in Huntington’s disease, hippocampus, and cortex in Alzheimer’s disease, 
cerebellum in spinal-cerebellar ataxias, spinal cord in amyotrophic lateral sclerosis, and 
spinal cord injury), and distinct transduction profiles by different rAAVs.  
Striatum. Previous studies have shown that systemic injection of rAAV9 in neonatal mice 
yields robust striatal transduction (Foust et al., 2009). In this study, a large number of 
neurons were also transduced by rAAVrh.10, confirmed by costaining with a neuronal 
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marker [Figure 2.2]. Other vectors, including rAAVrh.39, rAAVrh.43 and rAAV7, also 
mediated moderate transduction in striatum. In contrast, rAAV6, rAAV6.2, and rAAV1 
resulted in relatively lower EGFP expression in this structure [Figure 2.2].  
Hippocampus. Large numbers of EGFP-positive neurons were observed bilaterally in all 
regions of the hippocampus, namely dentate gyrus, hilus, CA1, CA2, and CA3 for the 
mice that received intravenous rAAVrh.10, rAAV9, rAAV7, rAAVrh.39, and rAAVrh.43 
(ranked by transduction efficiency in this structure, Table 2.1 and Figures 2.1 & 2.2). In 
addition to the neuronal transduction pattern, we also observed EGFP-positive cells that 
morphologically resembled astrocytes [Figure 2.2]. This was further confirmed by double 
staining with antibodies against EGFP and GFAP, an astrocyte marker. For intravenously 
delivered rAAV1, rAAV6, and rAAV6.2 only a small proportion of EGFP-positive cells 
in the hippocampus [Figure 2.2].  
Cortex. AAV7, AAV9, AAVrh.10, AAVrh.39, and AAVrh.43 vectors achieved moderate 
EGFP transduction in cortex targeting mainly neurons and astrocytes [Table 2.1 and 
Figures 2.1 & 2.2]. Prominent EGFP-positive cells were typically observed in the 
ventrolateral regions of the cortex, including posterior agranular insular cortex, piriform 
cortex, lateral entorhinal cortex, posterolateral cortical amygdaloid nucleus, and 
posteromedial cortical amygdaloid nucleus [Figure 2.2]. The cortical transduction 
efficiency of rAAVrh.10, rAAV9, rAAVrh.39, and rAAVrh.43 was comparable. AAV1, 
AAV6, and AAV6.2 vectors also transduced cortical cells, albeit at considerably lower 
levels than the rAAV vectors mentioned above [Figure 2.2]. 
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Figure 2.2 Strong and widespread EGFP expression in mouse brain after neonatal 
injections. 4 × 1011 genome copies of rAAVs vectors were injected into neonatal 
postnatal day 1 (P1) pups, and distribution of EGFP expression in the brain was analyzed 
at 21 days post-injection. 40 micrometer thick cryosections were stained with an anti-
EGFP antibody for immunofluorescence. The regions shown are: olfactory bulb, 
striatum, hippocampus, cortex, hypothalamus, cerebellum, and medulla. Representative 
sections are shown for each rAAV. Bars = 100 μm. EGFP, enhanced green fluorescent 
protein; rAAV, recombinant adeno-associated virus. 
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Figure 2.2 Strong and widespread EGFP expression in mouse brain after neonatal 
injections.  
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Hypothalamus. The most impressive EGFP signal was observed in the hypothalamus for 
all eight effective vectors. Intravenous administration of rAAVrh.10 resulted in EGFP 
expression in the entire hypothalamus, followed by rAAVrh.39, rAAV7, rAAV6.2, 
rAAVrh.43, rAAV9, rAAV1, and rAAV6 [Table 2.1 and Figures 2.1 & 2.2]. Interestingly 
most EGFP-positive cells in this structure have an astrocytic morphology which was 
confirmed by immunostaining. The strong and widespread astrocytic EGFP signal tended 
to obscure direct examination of morphological details of other transduced cells.  
Cerebellum. EGFP-positive cells and fibers were easily detected in cerebellum for all 
rAAV vectors except for AAV2 and AAV5 [Table 2.1 and Figures 2.1 & 2.2]. A large 
number of EGFP-expressing cells were found in the Purkinje and granule cell layers for 
rAAV7, rAAV9, rAAVrh.10, rAAVrh.39, and rAAVrh.43 [Figure 2.2]. Interestingly, the 
transduction profile of rAAV1 vector was restricted to cells in the granule cell layer, 
while rAAV6 and rAAV6.2 were localized in cells in the Purkinje cell layer [Figure 2.2].  
Medulla. As above, all rAAVs, except for rAAV2 and rAAV5, mediated moderate to 
robust EGFP expression in medulla with most green cells being present in the outer rim 
[Figure 2.2]. Transduction efficiencies of these rAAV in this region are ranked in the 
following order: rAAVrh.39 = rAAVrh.43 > rAAV.rh10 > rAAV1 > rAAV9 > rAAV7 > 
rAAV6.2 > rAAV6 [Table 2.1 and Figures 2.1a]. Most EGFP-transduced cells had an 
astrocytic morphology.  
Spinal cord. rAAVrh.10, rAAV9, rAAVrh.39, and rAAVrh.43 gave rise to robust EGFP 
expression in cervical gray and white matter, while rAAV1, rAAV6.2, and rAAV7 
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showed moderate EGFP expression [Table 2.1 and Figures 2.1 & 2.3]. The EGFP signal 
was observed only in white matter for rAAV1. The transduction ability of all rAAVs 
decreased from cervical to lumbar spinal cord, although EGFP-positive cells were still 
visible in the latter region. Large populations of EGFP-positive cells with astrocytic 
morphology were observed throughout the spinal cord [Figure 2.3]. Additionally, 
rAAVrh.10, rAAV9, rAAVrh.39, rAAVrh.43, and rAAV7 also transduced cells with 
motor neuron morphology in the ventral regions of the spinal cord [Figure 2.3]. 
Ascending dorsal column fibers and dorsal root ganglia displayed remarkable 
transduction with strong EGFP expression in dorsal root ganglia neurons [Figures 2.4a & 
b]. The identities of rAAV transduced cell types in the spinal cord were characterized by 
co-immunofluorescence staining with antibodies against EGFP and cell-specific markers. 
Seven rAAV vectors can achieve efficient global transduction of the adult mouse CNS 
where AAVrh.8 is the best 
 To determine the transduction efficiency of each serotype after intravenous 
injection in adult mice, we detected and quantified the enhanced green fluorescent protein 
(EGFP) signal from the coronal sections of brains and transversal sections of cervical, 
thoracic, and lumbar spinal cords [Figures 2.5, 2.6 & 2.7]. Based on the density of the 
transduced cells, we grouped 12 rAAVs into four groups [Figures 2.5, 2.6; Table 2.2]. 
Group 1 consisted of rAAVrh.8, rAAVrh.10, and rAAV9. This group ranked consistently 
as the top three in the transduction levels in both brain and spinal cord; the only exception 
being the spinal cord neurons, where the top seven vectors showed similar levels of  
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Figure 2.3 EGFP expression in mouse spinal cord after neonatal intravenous 
injection of rAAVs. 4 × 1011 genome copies of rAAVs were injected into neonatal 
postnatal day 1 (P1) pups, and distribution of EGFP expression in the spinal cord was 
analyzed at 21 days post-injection. Forty micrometer thick cryosections from cervical, 
thoracic and lumbar regions were stained with an anti-EGFP antibody for 
immunofluorescence. Representative sections are shown for each rAAV. Bars = 100μm. 
EGFP, enhanced green fluorescent protein; rAAV, recombinant adeno-associated virus. 
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Figure 2.3 EGFP expression in mouse spinal cord after neonatal intravenous 
injection of rAAVs.  
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Figure 2.4 Transduction of dorsal root ganglia after neonatal intravascular infusion 
of rAAVs Neonatal P1 pups received 4×1011 GCs of rAAVs and EGFP expression in 
dorsal root ganglia analyzed at 21 days post-injection. (a) EGFP expression in dorsal root 
ganglia neurons was analyzed by double immunofluorescence staining for EGFP (green) 
and a neuronal-specific marker (NeuN, red) for systemically delivered rAAVs 7, 9, rh.10 
and rh39.  (b) Transduction of neonatal mouse dorsal root ganglia by systemically 
delivered rAAVs 1, 6, 6.2 and rh43 was stained only using anti-EGFP antibody. Scale 
bars represent 75μm. 
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Figure 2.4 Transduction of dorsal root ganglia after neonatal intravascular infusion 
of rAAVs.  
a. 
 
b. 
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Figure 2.5 General transduction characteristics of 12 rAAVs in the adult mouse 
brain. rAAVEGFPs were injected into the tail vein of 10-week old mice at 4×1012 
genome copies (GCs) per mouse (n = 3). Forty micrometer frozen sections of central 
nervous system (CNS) tissues were obtained 21 days postinjection and stained with 
antibody against EGFP. Staining was visualized with an avidin–biotin complex/3,3′ -
diaminobenzidine substrate system. Shown are composite images of bregma -2.00 mm 
brain sections of rAAV-injected mice organized into four groups based on EGFP 
semiquantitative score and extend of distribution. Bar = 1,000 μm. EGFP, enhanced 
green fluorescent protein. 
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Figure 2.5 General transduction characteristics of 12 rAAVs in the adult mouse 
brain.  
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Figure 2.6 General transduction characteristics of 12 rAAVs in the adult mouse 
spinal cord. rAAVEGFPs were injected into the tail vein of 10-week old mice at 4 × 1012 
genome copies (GCs) per mouse (for further description, see Figure 1, n = 3). Shown are 
composite images of cervical spinal cord, thoracic spinal cord, and lumbar spinal cord 
sections of rAAV-injected mice organized into four groups based on EGFP 
semiquantitative score and extent of distribution. Bar = 250μm. 
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Figure 2.6 General transduction characteristics of 12 rAAVs in the adult mouse 
spinal cord. 
 
 
63 
 
Figure 2.7 Quantification of transduced cell types in the central nervous system 
(CNS) of adult mice.  EGFP-positive CNS cell types are microscopically scored, and the 
means of (e,h) rAAV transduced astrocytes, (d,g) neurons, and (f,i) oligodendrocytes in 
the (b,d–f) brains and (c,g–i) spinal cords are shown (n = 3). **P < 0.0033, ***P < 0.001, 
****P < 0.0001. ns, not significant. 
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Figure 2.7 Quantification of transduced cell types in the central nervous system 
(CNS) of adult mice.   
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transduction [Figures 2.7g & 2.8]. Group 2 had four vectors, rAAV7, rAAV8, 
rAARrh.39, and rAAVrh.43 and ranked lower than the group 1; however their overall 
transduction levels were still excellent. In some cases (e.g., total spinal cord and spinal 
cord neurons), the differences between this group and group 1 were small and 
insignificant [Figures 2.5, 2.6 & 2.7c&g; Table 2.2]. All group 1 and group 2 vectors 
transduced spinal cord motor neurons robustly [Figure 2.8]. Group 3 consisted of three 
vectors, rAAV1, rAAV6, and rAAV6.2. The transduction levels by this group were lower 
than groups 1 and 2. In most instances, rAAV6.2 ranked the highest and the AAV1 the 
lowest within this group [Figures 2.5, 2.6, 2.7 & 2.8]. Group 4 consists of two vectors, 
rAAV2 and rAAV5.This group had the lowest transduction levels [Figures 2.5, 2.6 & 
2.7]. Based on these assessments, we focused our detailed analysis on the group 1 vectors 
and some representatives of group 2 and group 3 vectors. The group 1 vectors transduced 
cells in wide areas of the CNS, including cortex, striatum, hippocampus, thalamus, 
hypothalamus, amygdala, corpus callosum [Figures 2.5, 2.9, 2.10 & 2.11], the choroid 
plexus [Figure 2.12], and all three spinal cord regions (i.e., cervical, thoracic, and lumbar) 
[Figures 2.6 & 2.8]. Overall, rAAVrh.8 appeared to transduce most robustly relative to 
other vectors. rAAVrh.8 consistently ranked first in different regions and in different cell 
types [Figure 2.7] by a semiquantitative scoring system (see Materials and Methods). The 
only exceptions were the spinal neurons, where the top seven serotypes had the same 
transduction efficiency [Figure 2.7g]. 
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Table 2.2 Groups of rAAVs based on transduction efficiency. 
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Figure 2.8 Motor neuron transduction patterns of different rAAVEGFPs in the 
lumbar spinal cords of adult mice.  
rAAVvectors were injected into the tail vein of 10-week-old mice at 4×1012 genome 
copies per mouse. Staining for EGFP was carried out as described in Figure 1 legend. 
Shown are the compilation of high-magnification images of central nervous system 
(CNS) cell transduction and their corresponding locations in a low-magnification view    
Bars, 20µm. 
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Figure 2.8 Motor neuron transduction patterns of different rAAVEGFPs in the 
lumbar spinal cords of adult mice. 
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Figure 2.9 Transduction profiles of various neuronal populations by rAAVrh.8. 
rAAVrh.8 vectors were injected into the tail vein of 10-week-old mice at 4×1012 genome 
copies per mouse. Staining for EGFP was carried out as described in Figure 1 legend. 
Shown are the compilation of high-magnification images of central nervous system 
(CNS) cell transduction and their corresponding locations in a low-magnification view at 
bregma -2.00 mm (a–i) as well as some other clinical relevant brain regions (i.e., 
olfactory bulb (OB), substantia nigra (SN), and lateral septal nucleus (LSN) and 
cerebellum) that were not present in the lower magnification view of the selected brain 
section. CC, corpus callosum; CA2, CA2 region of hippocampus; DG, dentate gyrus; PC, 
piriform cortex. Scale bars in a, c, h = 10µm; in d, f, i = 15µm, and b, e, g = 20µm. 
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Figure 2.9 Transduction profiles of various neuronal populations by rAAVrh.8. 
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Figure 2.10 Regional transduction patterns of rAAVs in the adult mouse brains. 
rAAV vectors were injected into the tail vein of 10-week-old mice at 4×1012 genome 
copies per mouse. Staining for EGFP was carried out as described in Figure 1 legend. 
Shown is the compilation of low-magnification images of central nervous system (CNS) 
regions. Bars = 20µm.  
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Figure 2.10 Regional transduction patterns of rAAVs in the adult mouse brains.  
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Figure 2.11 Transduction profiles of various neuronal populations by rAAVrh.10 
and 9. rAAVvectors were injected into the tail vein of 10-week-old mice at 4×1012 
genome copies per mouse. Staining for EGFP was carried out as described in Figure 1 
legend. Shown is the compilation of high-magnification images of central nervous system 
(CNS) regions. Bars = 20µm.  
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Figure 2.11 Transduction profiles of various neuronal populations by rAAVrh.10 
and 9. 
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Figure 2.12 Choroid plexus transduction pattern of different I.V. delivered rAAV 
serotypes in mouse. rAAV vectors were injected into the tail vein of 10-week-old mice 
at 4×1012 genome copies per mouse. Staining for EGFP was carried out as described in 
Figure 1 legend. Shown is the compilation of low-magnification images of the choroid 
plexus above the third ventricle. Bars = 20µm.  
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Figure 2.12 Choroid plexus transduction pattern of different I.V. delivered rAAV 
serotypes in mouse. 
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Intravenous rAAV administration leads to transduction of different cell types in the 
CNS 
Neonatal injections: To confirm the identity of transduced cells in different regions of the 
CNS, we performed double immunofluorescent staining with antibodies against EGFP 
and NeuN (generic neuronal marker), glial fibrillary acid protein (GFAP; astrocyte 
marker), calbindin-D28K (Purkinje cell marker), choline acetyl transferase (ChAT; motor 
neuron marker), and tyrosine hydroxylase (TH; marker of dopaminergic neurons) [Figure 
2.13]. The immunostaining results showed that a large number of NeuN positive cells 
expressed EGFP throughout the mouse brain, which indicated widespread neuronal 
transduction. The regions with high density of transduced neurons included striatum, 
hippocampus, cortex, and hypothalamus. rAAVrh.10, rAAV9, rAAV7, and rAAVrh.39 
vectors are very efficient in mediating neuronal transduction, followed by rAAV6.2, 
rAAV1, and rAAV6 [Figures 2.2 & 2.13]. The most abundant transduced cells 
throughout the CNS were the GFAP-positive astrocytes with small cell bodies and highly 
ramified processes [Figure 2.13]. The calbindin-D28K immunostaining confirmed the 
identity of a large number of transduced cells in the cerebellum as Purkinje cells, with 
robust EGFP expression in both cell body and their tree-like processes [Figure 2.13]. The 
rAAVs proficient in transducing Purkinje cells include: rAAVrh.10, rAAV9, rAAVrh.39, 
rAAV7, rAAV6.2, and rAAVrh.43. rAAV1 and rAAV6 only transduced a small portion 
of Purkinje cells with low EGFP intensity [Figure 2.2]. Transduction of motor neurons 
was confirmed by the presence of large EGFP+/ChAT+ cells in the ventral spinal cord 
for several rAAV vectors [Figure 2.13]. rAAVrh.10, rAAV9, rAAV7, rAAVrh.39 
78 
 
showed comparable high efficiency transduction of motor neurons [Figure 2.3]. TH+ 
dopaminergic neurons in the substantia nigra were also transduced [Figure 2.13]. 
Adult injections: The group 1, 2, and 3 vectors transduce multiple cell types and various 
neuronal populations in the CNS. To identify the cell types that the vectors transduce, we 
first carried out morphological analysis on the CNS tissue sections stained for GFP. By 
high-magnification microscopy, we observed extensive transduction of neurons, 
astrocytes, and oligodendrocytes in various areas of the CNS [Figures 2.7, 2.8, 2.9, 2.10 
& 2.11]. For example, the group 1 vectors transduced granular cells in dentate gyrus 
[Figure 2.9b, 2.10 & 2.11b], pyramidal neurons in CA2 [Figure 2.9d, 2.10 & 2.11d], 
medial spiny neurons and astrocytes in striatum [Figure 2.9e, 2.10 & 2.11e ], Purkinje 
neurons in cerebellum [Figure 2.9, 2.10 &2.11j], neurons and astrocytes in thalamus 
[Figure 2.9h, 2.10 & 2.11h], hypothalamus  [Figure 2.9g & 2.11g], amygdala  [Figure 
2.9i & 2.11i], layer 3–6 of the cortex  [Figure 2.9a, f, 2.10 & 2.11a, f], substantia nigra  
[Figure 2.9 & 2.11k] and lateral septal nucleus (LSN) [Figure 2.9h & 2.11l]. 
Additionally, they also transduced oligodendrocytes in corpus callosum  [Figure 2.9c, 
2.10 & 2.11c]. A similar cellular transduction pattern was also observed for group 2 and 3 
vectors, albeit that the density of transduced cells was lower than group 1 vectors 
[Figures 2.5, 2.6 & 2.10].  
To verify the transduced cell types, we performed double fluorescence staining on 
the rAAVrh.8-treated CNS tissues. Using markers for specific cell types, including NeuN 
for neurons, glial fibrillary acidic protein for astrocytes, adenomatous polyposis coli for 
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oligodendrocytes, Iba1 for microglia, and CD31 for blood vessels, we verified that EGFP 
was expressed in neurons, astrocytes, oligodendrocytes, and blood vessels but not in 
microglia [Figure 2.14].We also verified EGFP expression in several specific neuronal 
subpopulations, including Purkinje cells (calbindin), motor neurons (ChAT), medial 
spiny neurons (Darpp-32), and dopaminergic neurons (tyrosine hydroxylase) [Figure 
2.15]. 
Intravenous administration of AAV vectors in neonates mediated robust transduction 
in ventricles and brain blood vessels 
Strong EGFP expression was observed in choroid plexus cells in lateral, 3rd and 
4th ventricles of the animals infused with rAAVrh.39, rAAVrh.10, rAAVrh.43, rAAV7, 
and rAAV9 (ranked by transduction efficiency) [Table 2.1 & Figure 2.16]. Ependymal 
cells lining the ventricles were also transduced. An interesting observation was an 
apparent gradient with the highest number of eGFP transduced cells in periventricular 
regions and progressively lower numbers with increasing distance from the ventricles. 
This was more obvious around the 3rd and 4th ventricles than the lateral ventricles 
[Figure 2.16]. Extensive EGFP signal was also found associated with blood vessels 
throughout the brain and spinal cord. This was verified by dual immunofluorescence 
staining for EGFP and a blood vessel endothelium specific marker, CD34. [Figure 2.17a 
& b]. Unlike the distinct rAAV transduction profiles in different regions of the brain 
parenchyma, the EGFP transduction of blood vessels throughout the CNS seemed to be 
quite uniform for any given vector.  
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Intravenous injection of AAV vectors did not cause microgliosis in neonates 
Brain sections were stained for microgial cells using Iba1. Iba-1-positive cells in 
the brain of rAAVrh.10-infused mice were comparable to PBS-injected mice [Figure 
2.18]. This result suggested that intravascularly delivered rAAVs do not cause sustained 
inflammation in the CNS of mice 3 weeks after the injection of P1 neonates. However, it 
remains to be determined if facial vein injection of rAAVs caused any acute microgliosis 
in the CNS at the neonatal stage since the present analysis was performed 3 weeks later.  
rAAVrh.8 injections result in reduced peripheral tissue dissemination in adult mice 
In addition to strong and widespread transduction in the CNS, low peripheral 
tropism is an important property of an ideal viral vector for systemically delivered CNS-
targeted gene therapy. To characterize biodistribution profiles of intravenous delivered 
rAAV in various tissues of the injected mice, qPCR quantification of rAAV genomes was 
carried out for the group 1 vectors in brain, spinal cord, lung, kidney, pancreas, skeletal 
muscle, heart, and liver tissues [Figure 2.19a]. Persistent rAAVrh.8 genomes were similar 
in amounts to those of rAAV9 and rAAVrh.10 in the brain but significantly lower in the 
liver. To assess the degree of transduction in the brain relative to peripheral tissues, we 
calculated ratios between the genome copies in the brain and periphery. There was no 
significant difference between the vectors in the group 1 probably due to a high degree of 
variation among the injected animals [Figure 2.19b]. Nevertheless, we observed a trend 
toward relatively high CNS transduction over the periphery for rAAVrh.8 compared with 
rAAVrh.10 and rAAV9.  
81 
 
Figure 2.13 Analysis of transduced cell phenotype in mouse CNS after neonatal 
intravascular delivery of rAAVs. 
Forty micrometer thick sections of brain and spinal cord from AAV-injected mice were 
stained for immunofluorescence using antibodies against EGFP and cell-type specific 
markers for neurons [neuronal-specific marker (NeuN)], astrocytes [glial fibrillary acid 
protein (GFAP)], cerebellar Purkinje cells (calbindin-D-28k), spinal cord motor neurons 
[choline acetyl transferase (ChAT)], and dopaminergic neurons in the sustantia nigra 
[Tyrosine hydroxylase (TH)]. All rAAVs were examined, but for each cell type, only one 
representative picture is shown. Scale bars sizes are indicated in each picture. AAV, 
adeno-associated virus; CNS, central nervous system. 
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Figure 2.13 Analysis of transduced cell phenotype in mouse CNS after neonatal 
intravascular delivery of rAAVs.  
83 
 
Figure 2.14 Identification of cell types transduced in the CNS of adult mice injected 
with rAAVrh.8EGFP. Sections were stained with antibodies against EGFP, NeuN 
(neurons), GFAP (astrocytes), APC (oligodendrocytes), Iba1 (microglia), CD31 (blood 
vessels). Objective ×60. Bar = 20 µm. APC, adenomatous polyposis coli; GFAP, glial 
fibrillary acidic protein. 
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Figure 2.14 Identification of cell types transduced in the CNS of adult mice injected 
with rAAVrh.8EGFP. 
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Figure 2.15 Identification of neuronal populations transduced in the CNS of adult 
mice injected with rAAVrh.8EGFP Sections were stained with antibodies against 
EGFP, calbindin (Purkinge cells); ChAT (Motor neurons); Darpp32 (medial spiny 
neurons) and TH (dopaminergic neurons Objective ×60. Bar = 20 µm. ChAT, Choline 
acetyl trasnferase; TH, Tyrosine hydroxylase. 
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Figure 2.15 Identification of neuronal populations transduced in the CNS of adult 
mice injected with rAAVrh.8EGFP. 
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Discussion 
Though it is well documented that intravascular-delivered rAAVs are excellent 
vectors for CNS gene therapy in neonatal animals (Foust et al., 2009; Rahim et al., 2011), 
there is no comprehensive characterization of such vectors. We characterized the CNS 
transduction profile of 10 different rAAV vectors delivered by intravascular infusion in 
neonatal mice and found eight out of ten rAAVs can cross the BBB and mediate gene 
transfer to the neonatal mouse CNS with varying degrees of efficiency [Figures 2.1, 2.2 
& 2.3 and Table 2.1]. After systemic administration, rAAVrh.10, rAAVrh.39, 
rAAVrh.43, and rAAV9 are the most effective rAAVs with similar transduction 
capabilities and cellular tropism, as assessed by overall EGFP expression in the CNS. 
Specifically, a number of regions in the mouse CNS, including striatum, hippocampus, 
cortex, hypothalamus, cerebellum, medulla, and cervical spinal cord, all revealed 
substantial EGFP expression. In addition, rAAV6.2 and rAAV7 were also very effective, 
but the efficiencies of EGFP transduction in the targeted regions were consistently lower 
than those obtained with the four top vectors. Still further down the spectrum were 
rAAV1 and rAAV6, which did achieve some CNS transduction, but their efficiency was 
quite low. Finally, rAAV2 and rAAV5 revealed little or no CNS gene delivery after 
systemic administration [Table 2.1]. It is worth noting that native EGFP expression was 
clearly detectable in brain and spinal cord sections for most of the rAAVs without 
immunostaining, which further demonstrates the robustness and extensiveness of CNS 
transduction in our study [Figure 2.20]. 
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In addition to the global delivery properties of several rAAVs described above, 
some rAAVs showed unique transduction profiles in the CNS. For instance, rAAV1 
primarily transduced granule cells in the cerebellum, while rAAV6 and rAAV6.2 mostly 
transduced Purkinje cells, and yet others transduced both [Figure 2.2]. This suggests that 
once across the BBB, the rAAVs display different tropisms, which can be attributed to 
the capsid given that the vector genome used in all vectors was the same. 
 The situation however would be different in adult mice where intravenous 
injected rAAVs would generate limited CNS transduction due to the advanced BBB 
development (Fu et al., 2003; Manfredsson et al., 2009). We demonstrate that several 
rAAVs are capable of crossing the BBB efficiently following intravenous injection in 
adult animals using a semiquantitative scoring system (Cearley et al., 2008). We do, 
however, recognize that this system has disadvantages in assessing absolute differences 
between serotypes and more extensive quantitative analyses are needed. Another caveat 
of this study is the number of animals per group (n = 3). Although, three to four animals 
per group are widely used to evaluate the transduction efficiency of rAAV (Cearley and 
Wolfe, 2006; Fu et al., 2003; Gray et al., 2011; Zincarelli et al., 2008), animal-to-animal 
variations even with inbred animals may influence the final results. To minimize this 
possibility, we exclusively injected male mice. Despite the limitations of the method, the 
semiquantitative characterization provides useful reference points for the future use of 
these AAV serotypes for intravenous delivery. 
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Figure 2.16 Efficient transduction of brain ventricular structures after intravascular 
delivery of rAAVs in neonatal mice. The choroid plexus appears to be transduced at 
high efficiency for multiple rAAV. Bars = 100 μm. 
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Figure 2.16 Efficient transduction of brain ventricular structures after intravascular 
delivery of rAAVs in neonatal mice. 
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Figure 2.17 Transduction of the brain capillary vessels by intravascularly delivered 
rAAVs. Sections were stained with antibodies against EGFP to show staining of blood 
vessels. Lower panel shows representative brain section showing specificity of staining 
by using antibodies against both eGFP and CD34 (blood vessels). Objective ×60. Bar = 
20 µm. 
92 
 
Figure 2.17 Transduction of the brain capillary vessels by intravascularly delivered 
rAAVs. 
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Figure 2.18 Evaluation of microgliosis in mice brain after systemic delivery of 
rAAVs to P1 neonates. Forty micrometer brain sections were stained with antibodies 
against Iba1 for microgliosis (blood vessels). Objective ×60. Bar = 20 µm. 
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Figure 2.18 Evaluation of microgliosis in mice brain after systemic delivery of 
rAAVs to P1 neonates. 
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Figure 2.19 Biodistribution Profiles in mice. (a) Biodistribution profiles of 
rAAVEGFPs in the adult mice after intravenous injections. Persistent rAAV-EGFP 
vector genomes in eight different tissues of rAAV-treated mice were quantified by 
quantitative polymerase chain reaction using primers/probe set targeting poly A region of 
the vector genome (n = 3). (b). Ratios of vector genomes detected in the brains to those in 
the liver, heart, lung, and pancreas tissues respectively (n = 3). ****P < 0.0001. ns, not 
significant. 
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 Figure 2.19 Biodistribution Profiles in mice. 
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Figure 2.20 Native EGFP expression in mice CNS after systemic delivery of rAAVs 
to P1 neonates. Neonatal P1 pups received 4×1011 GCs of rAAVs and EGFP expression 
analyzed at 21 days post-injection. Forty micron thick cryosections were mounted on 
slides and EGFP expression observed without immunostaining. The exposure times for 
each image are indicated. 
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Figure 2.20 Native EGFP expression in mice CNS after systemic delivery of rAAVs 
to P1 neonates. 
 
99 
 
Of all the rAAV serotypes tested in adult animals, the most robust in crossing the 
BBB are the group 1 vectors consisted of rAAV8, rh.10, and 9 [Figures 2.5, 2.6, 2.7 & 
Table 2.2]. Although less robust than the group 1 vectors, the group 2 vectors, consisted 
of rAAV8, 7, rh.43, and rh.39, also show strong capability of transducing cells in broad 
CNS areas following intravenous injection. These results suggest that the group 1 and 
group 2 vectors achieve similar results and expand the repertoire to be used as alternative 
vectors to deliver therapeutic genes for treating CNS diseases via intravenous injection. 
Among the top vectors, one that particularly stands out is the rAAVrh.8. With its 
global and robust transduction of the CNS cells, rAAVrh.8 consistently ranked first in 
broad CNS areas and in different cell populations [Figure 2.7]. A particularly attractive 
feature for rAAVrh.8 is its naturally lower peripheral tissue dissemination than other 
vectors, particularly in the liver [Figure 2.19], which enhances the safety profile of 
systemic gene delivery to the CNS. These qualities suggest that rAAVrh.8 is a top 
candidate vector for the treatment of the CNS diseases that afflict broad areas of the CNS. 
The robust transduction of the CNS cells following intravenous injection is a 
surprising but useful character of some rAAV vectors. How these rAAVs cross the BBB 
remains elusive (Daya and Berns, 2008; Di Pasquale et al., 2003; Manfredsson et al., 
2009). The fact that different AAV serotypes can efficiently transduce brain capillary 
endothelial cells, neurons, and astrocytes in neonatal animals strongly suggest that these 
vectors are able to extravasate from the circulation and reach the CNS parenchyma, 
possibly by crossing the BBB (Wolburg and Paulus, 2010). Our results in adult animals 
100 
 
suggest two possible routes for the rAAVs to enter and transduce the CNS. First, the 
rAAVs may cross the BBB by exploiting the fenestrated capillary vessels of 
circumventricular organs (Duvernoy and Risold, 2007). This is supported by the fact that 
we consistently observed strong EGFP expression in or near circumventricular organs 
such as the choroid plexus, ventricles [Figures 2.12 & 2.16] specially the third ventricle 
[Figure 2.10] and ependymal cells (e.g., see ventricle below corpus callosum in the 
rAAVrh.43 and rAAVrh.10 panels in Figure 2.10]. The second possibility is direct 
transcytosis of rAAVs via the innermost layer of blood vessels (Di Pasquale et al., 2003). 
In the neonatal study too, choroid plexuses and their surrounding parenchymal tissue 
were efficiently transduced. In addition, there was an apparent gradient of EGFP intensity 
from periventricular (higher) to deep parenchymal (lower) tissue. These observations 
suggest an alternate route for AAV entry into the neonatal murine CNS through the 
choroid plexus (Wolburg and Paulus, 2010), followed by widespread distribution via CSF 
and/or interstitial fluid flow to transduce neuronal and glial cells. Perivascular astrocytes 
have been shown to regulate the tightness and exchange of molecules across the BBB 
(Abbott et al., 2006; Janzer and Raff, 1987). Therefore, the presence of intensely stained 
blood vessels and their surrounding astrocytes suggest that rAAVs use this second route 
of entry into the CNS [Figures 2.14 & 2.17]. Further studies will be needed to understand 
the transduction mechanism of rAAVs. 
In summary, our study has revealed that many rAAVs are capable of crossing the 
BBB and transducing the CNS cells in both neonates as well as in adults. Of these, the 
group 1 vectors, including rAAVrh.8, rAAVrh.10, and rAAV9 have demonstrated the 
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strongest capacity for transducing CNS cells after the systemic intravenous injection. 
Importantly, rAAVrh.8 appears superior to its group 1 peers in its global CNS 
transduction and decreased peripheral tissue targeting, and thus, is currently the best 
option for delivering CNS gene therapy via intravenous injection in adult animals. 
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CHAPTER III: A SINGLE INTRAVENOUS rAAV INJECTION AS LATE AS P20 
ACHIEVES EFFICACIOUS AND SUSTAINED CNS GENE THERAPY IN 
CANAVAN MICE 
The following chapter contains the manuscript: 
Ahmed SS, Li H, Cao C, Sikoglu EM, Denninger AR, Su Q, Eaton S, Liso Navarro AA, 
Xie J, Szucs S, Zhang H, Moore C, Kirschner DA, Seyfried TN, Flotte TR, Matalon R, 
Gao G.(2013) A single intravenous rAAV injection as late as P20 achieves efficacious 
and sustained CNS Gene therapy in Canavan mice. Molecular Therapy Dec; 
21(12):2136-47 [PMID: 23817205]. 
The study was devised and results were interpreted by me under the supervision of Dr 
Gao. All experiments except for the ones listed below have been performed by me. 
Figure 3.2c was prepared by Dr Huapeng Li. Figures 3.2 f,g and were prepared by Dr Elif 
Sikoglu, Ana Navarro and Dr Constance Moore while data for Figures 3.3c, d was 
provided by them; figures were analyzed and assembled by me. Figure 3,2 h was 
provided by Sylvia Szucs. Figure 3.6 c, d , Fig 3.7, Tables 3.1 and 3.2 were contributed 
by Dr Thomas Seyfried and Samuel Eaton. Figure 3.8 was contributed by Andrew 
Denninger and Dr Daniel Kirschner. Viral vectors were made by Qin Su. CD mice were 
provided by Dr Reuben Matalon. Electron Microscopy was done by the EM Core at 
UMass Medical School. The manuscript was prepared by me and Dr Gao. 
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CHAPTER III: A Single Intravenous rAAV Injection as Late as P20 Achieves 
Efficacious and Sustained CNS Gene Therapy in Canavan Mice 
Introduction 
Canavan disease (CD) is a rare lethal pediatric leukodystrophy characterized by 
extensive demyelination, edema, and progressive spongy degeneration of the central 
nervous system (CNS) (Van Bogaert L, 1949). Currently, there is no effective treatment. 
Clinical symptoms include blindness, severe psychomotor retardation and early death 
(Beaudet, 2001; Matalon and Michals-Matalon, 2000; Traeger and Rapin, 1998). CD is 
caused by autosomal recessive mutations in aspartoacylase (AspA) (EC 3.5.1.15) (Kaul et 
al., 1993; Matalon et al., 1988); an enzyme that deacetylates N-acetyl aspartic acid 
(NAA) to produce aspartic acid and acetate (Baslow and Resnik, 1997; Birnbaum et al., 
1952 ). Since the NAA accumulates mainly in the urine, NAA aciduria provides a unique 
biomarker for CD (Matalon et al., 1988).  
The first AspA knockout mouse strain was engineered by an insertional 
interruption in exon 4 of the AspA gene. These mice, also known as CD mice, have a 
short lifespan (<4 weeks), hydrocephaly, NAA aciduria, extensive white matter 
vacuolation and motor dysfunction providing a bona-fide model to study the severest 
forms of CD (Matalon et al., 2000). In addition, there is a naturally occurring CD model, 
called tremor rat with a large deletion spanning four genes including AspA as well as two 
other more recently created mouse models, all of which have less severe phenotypes and 
near normal lifespans (Kitada et al., 2000; Mersmann et al., 2011; Traka et al., 2008). 
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Gene replacement therapy is a promising clinical intervention for inborn errors 
like CD. Novel recombinant adeno associated viruses (rAAVs) derived from primates 
represent a promising gene delivery platform because of their wide range of tissue 
tropism, low immunogenicity, highly efficient and sustained gene transduction, and 
clinically proven track record in safety (Gao et al., 2002; Mingozzi and High, 2007). In 
an earlier gene therapy attempt for CD, 23 patients were treated with multiple-site 
intracranial injections of the first-generation rAAV2 (Janson et al., 2002). A follow-up 
study on 13 of these patients revealed the safety of rAAV-mediated therapeutic gene 
transfer to the CNS over a decade. The treatment resulted in slight reductions of NAA 
levels in some brain regions; but importantly, it indicated the necessity of early 
intervention in CD patients. This study also suggests that a global CNS gene transfer is 
necessary for alleviating widespread neuropathology in CD patients (Leone et al., 2012). 
Thus, one potentially viable strategy for CD gene therapy to target the CNS 
globally is through intravenous (IV) gene delivery using novel rAAVs that can cross the 
blood-brain barrier (Foust et al., 2009). Based on the initial report on rAAV9, our 
expanded vector characterization study in neonatal mice as well as preliminary results 
from a separate comprehensive study to screen rAAVs for IV gene delivery to adult CNS 
(Yang et al., 2014; Zhang et al., 2011), we selected rAAV9, rAAVrh.8, and rAAVrh.10 
for our proof-of-concept gene therapy study. We also designed a therapeutic cassette 
containing microRNA-binding sites (miRNA-BS) to detarget rAAV expression from 
peripheral tissues to minimize potentially untoward consequences of IV delivery (Xie et 
al., 2010). 
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An interesting alternative is to use endogenous microRNAs (miRNAs) to suppress 
transgene expression outside the CNS. miRNAs are small, noncoding RNAs that regulate 
gene expression by post-transcriptional silencing. miRNAs silence genes by two 
mechanisms. When partially complementary to mRNA sequences, they typically reduce 
target mRNA stability and protein expression by two- to fourfold or less, probably to tune 
mRNA expression (Bartel, 2009). In contrast, when miRNAs are nearly perfectly 
complementary to their mRNA targets, they cleave the mRNA, triggering its wholesale 
destruction (Brennecke et al., 2005). 
miRNA-binding sites were first used in lentiviral vectors to suppress transgene 
expression in hematopoietic cells, thereby attenuating transgene immunogenicity (Brown 
et al., 2006). The strategy was subsequently used to regulate naked DNA-mediated gene 
transfer, detarget oncolytic viral therapeutics from noncancer tissues to reduce host 
toxicity, and develop attenuated virus-based vaccines to reduce toxicity in recipients 
(Brown and Naldini, 2009). Since the systemic delivery of rAAVs may lead to possible 
off-target peripheral tissue expression, we explored the use of miRNAs to detarget 
rAAV9 expression both separately and concurrently in the liver, heart, and skeletal 
muscle, the three tissues most efficiently targeted by intravenously delivered rAAV9 
(Pacak et al., 2006; Xie et al., 2010; Zincarelli et al., 2008). One consideration is that 
intravascularly administered rAAV for CNS-targeted transduction requires suppressing 
high levels of rAAV expression in multiple peripheral tissues even when transgene 
transcripts are successfully expressed in the brain (Xie et al., 2010). Hence in addition to 
such endogenous miRNA-regulated restriction of transgene expression, an expanded 
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repertoire of rAAV vectors with strong tropism for the CNS and reduced affinity for 
peripheral tissues would also be important. This would limit potential peripheral toxicity, 
allow for greater therapeutic control and flexibility as well as bypass possible pre-existing 
immunity to rAAV9 in patient populations (Calcedo et al., 2009; Mingozzi and High, 
2007). 
Here, we documented progressive neuropathology and retinopathy in CD mice 
during early postnatal development. For gene therapy, we tested rAAV9, carrying the 
human AspA cDNA with and without miRNA regulation in CD mice by IV injections at 
postnatal day 0 (P0), which restored AspA activity, normalized NAA metabolism, 
alleviated neuropathy and retinopathy, and improved motor functions. We expanded P0 
injection study in CD mice to include rAAVrh.8 and rAAVrh.10, which improved their 
growth and extended survival up to 2 years (for rAAV9 and rAAVrh.8 groups thus far). 
Early lethality of CD mice (<4 weeks) was also completely rescued with rAAV9 
administration at P6, P13, and even P20, a few days before their death. We also 
demonstrate that AspA helps to maintain integrity of myelin sheaths and affects the 
content and distribution of myelin-enriched brain lipids. Most importantly, our study 
demonstrates, for the first time, an efficacious and sustained IV gene therapeutic for 
treating terminal stage CD mice as well as successful preclinical in vivo application of 
miRNA-regulated peripheral tissue detargeting in CNS-directed rAAV gene therapy. 
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Materials and Methods 
Viral production: All rAAV vectors were produced by transient transfection of 293 cells 
and CsCl gradient sedimentation as previously described (Sun et al., 2010) Vector 
preparations were titered by quantitative PCR, purity of vectors was assessed by 4–12 % 
SDS-acrylamide gel electrophoresis and silver staining (Invitrogen, Carlsbad, CA) and 
morphological integrity of virions was assessed by Transmission electron microscopy of 
negative stained recombinant AAV virions at Electron Microscopy Core, UMass Medical 
School, Worcester.  
Animal procedures: All animal procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC) of UMass Medical School. AspA+/- Sv129/Ev mice 
littermates were bred using programmatic timing and newborn pups were dosed on P0. 
Vectors were injected in the facial vein of P0 pups at doses of 4X1011 GC/mouse. P6, P13 
and P20 pups were injected in the retro-orbital sinus with 8X1011, 1.2X1012 and 4X1012 
GC/mouse respectively. After the injection pups were cleaned, rubbed with bedding, and 
then returned to their cage. The dam was reintroduced after brief nose numbing using 
ethanol pads. 
Immunohistochemistry: Animals were anesthetized, transcardially perfused with 4% 
paraformaldehyde (v/v) in PBS. Whole carcasses were postfixed in fixative for 1 day. 
Organs were extracted, rinsed in PBS, and sagitally sectioned. One half was 
cryoprotected in 30 % sucrose (w/v) in PBS at 4°C, embedded in OCT compound 
(Sakura Finetek, Torrance, CA) and frozen in a dry ice/ethanol bath. 40 μm floating 
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sections of the entire brain were cut in a Cryostat (Thermo Microm HM 550) for 
immunostaining. The other half was processed for Hematoxylin and Eosin staining for 
morphological studies.  
Floating sections were stained in 12-well plates. Sections were washed once in 
PBS for 5 mins, and incubated in blocking solution containing 0.05 % Tween-20 (v/v) 
(Fisher, Pittsburgh, PA), and 10 % goat serum (v/v) (Invitrogen) for 1 hour at room 
temperature. Sections were incubated with primary antibodies at 4°C overnight, washed 
twice in 0.05 % Tween-20 in PBS (PBST) for 15 mins each followed by incubation in 
appropriate secondary antibodies at room temperature for 1 hour. Sections were washed 
twice in PBST for 10 mins each before mounting on glass slides. Vectashield with 4ʹ,6 -
diamidino- 2-phenylindole (Vector Laboratories, Burlingame, CA) was used to mount all 
slides. Omission of either the primary or the secondary antibody in single-label 
experiments resulted in no labeling.  
The ABC stain was performed according to standard kit instructions (Elite ABC 
kit, Vectastain, Burlingame, California). DAB was used as the substrate for the 
peroxidase enzyme reaction (Vectastain).  
The primary antibodies used were as follows: mouse aspartoacylase (Abmart, 
New Jersey), rabbit aspartoacylase (provided by Dr Aryan Namboodiri); mouse NeuN 
(MAB-377, clone A60; Millipore); rabbit NeuN (ABN-78, Millipore) and appropriate 
secondary antibodies from Invitrogen. 
Imaging and Image Analysis: Stained sections were examined using DM 5500B Upright 
microscope (Leica Microsystems, Wetzlar, Germany), and images were captured with 
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Leica DFC365 FX high-sensitivity monochrome digital camera. Regions of interest were 
identified according to the mouse brain atlas. Z stack of images were taken with a 63X 
objective and 1.6X additional magnification for each channel and overlaid to obtain a 
multicolor image at 100.8X. Deconvolution was performed using Leica Application Suite 
Advanced Fluorescence software. 
Electroretinography (ERG): Mice were dark-adapted overnight and anesthetized with 
100 mg/kg ketamine and 20 mg/kg xylazine in saline before testing. Both pupils were 
topically dilated with phenylephrine hydrochloride and 1 % tropicamide, and mice were 
placed on a heated platform. Rod-dominated responses were elicited in the dark with 10 
μs flashes of white light (1.37 × 105 cd m−2) presented at intervals of 1 min in a Ganzfeld 
dome. ERGs were monitored simultaneously from both eyes with a silver wire loop 
electrode in contact with each cornea wetted with celluvisc containing Carboxy Methyl 
Cellulose Sodium 1 %. 
Western blot: Mice were sacrificed and their tissues were extracted and homogenized as 
described (Xie et al., 2010) . Protein in equal quantities was loaded into a 12% Tris–HCl 
gel well (Bio-Rad Laboratories, CA) and transferred to a nitrocellulose membrane (Bio-
Rad). The membrane was incubated in blocking buffer for 1hr followed by AspA 
polyclonal antibody overnight. After three washes in 0.1 % PBST, it was incubated with 
secondary antibodies conjugated to LI-COR IRDye for 1 hour at room temperature. After 
two washes with 0.1 % PBST signal was detected using the Odyssey Imager (LI-COR). 
Genome copy number:  rAAV genomes were quantified in 1µg of genomic DNA 
extracted from mouse tissues using the QIAamp DNA mini kit for quantitative detection 
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of vector genome copies by Taqman® probes (Applied Biosystems) with a single-copy 
endogenous GAPDH gene) as the diploid cell number reference. The Taqman® real-time 
PCR kit was run with primer sets which amplified regions of the nRBG poly A (Probe, 
6FAM-ATG AAG CCC CTT GAG CAT CTG ACT TCT-TAMRA; Fwd, GCC AAA 
AAT TAT GGG GAC AT; Rev, ATT CCA ACA CAC TAT TGC AAT G). The 
sensitivity of the assay was 10 copies/µg gDNA. 
AspA activity assay: Mice were sacrificed 3 months after injection, and brain 
homogenates were used for the enzyme assay (Matalon et al., 2000) . Briefly, the brain 
was homogenized and incubated with 50mM Tris–HCl (pH 8.0), 0.5% (w/v) NP-40, 50 
mM NaCl, 1 mM CaCl2, 2.8 mM NAA in a total volume of 600 µl. After incubation at 
37°C for 3h, the assay mixture was centrifuged and the supernatant was incubated with 
malic dehydrogenase, glutamic oxalacetic transaminase, and NADH for 10 min at 37°C. 
The amount of L-aspartate released was estimated by decrease in absorbance due to the 
conversion of NADH to NAD using a spectrophotometer (Shimadzu, MD) at 340 nm. 
One milliunit of aspartoacylase activity is equivalent to 1 nmol of aspartate released in 1 
min. Values were calculated using ANOVA. P <0.05 was considered significant. 
1H Magnetic Resonance Imaging and Spectroscopy study: Mice were anesthetized with 
2% isofluorane and constantly monitored for vital signs. All experiments were carried out 
on a Bruker 4.7T/40 cm horizontal magnet (Oxford, UK) equipped with 250 mT/m 
magnetic field gradient and interfaced with a ParaVision 4.0 console. A 1H 
radiofrequency (RF) coil configuration (Insight NeuroImaging Systems, MA) with inner 
diameter (ID) of 4 cm was used for the experiments.  
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T2-weighted anatomical images were acquired using a fast spin-echo sequence 
(RARE) (TR=3000 msec, TE=48 msec, matrix size=256×256, FOV=2.5 cm×2.5 cm, 
slice number=16, slice thickness=1 mm). 1H MRS Data was acquired using single voxel 
(Pont Resolved Spectroscopy Sequence (PRESS) (TR=2500 msec, TE=20 msec, 
Naverage=1024, voxel size=3 mm×3 mmX3 mm). 
Proton spectra were fit using LCModel (Version 6.2-2B) which  analyzed in vivo 
proton spectrum as a linear combination of model in vitro spectra from individual 
metabolite solutions (Provencher, 2001) and generated data as absolute fits (in 
institutional units) and standard deviations (SD%). Standard deviation was used as a 
measure of the reliability of the fit. The spectral inclusion criteria were SD less than 20% 
for NAA, Cr and Ins. 
Behavioral studies: Negative geotaxis test was performed on P7-P17 pups where they 
were placed on a 45° inclined plane; head facing downwards and their latency to turn 
with the head pointing upwards was recorded.  
For the beam balance test, animals were placed in the middle of a horizontal 
wooden balance beam (1.5 cm × 100 cm) with pads underneath to protect mice that might 
fall off the beam.  Latency to fall was recorded, with a 3min time limit for each trial.  
Neuromuscular function of the mice was assessed by testing grip strength on an 
inverted screen. Mice were placed in the center of a screen (30 cm2 square-wire mesh, 25 
mm2 holes) until they gripped the mesh. The screen was then inverted above a cushioned 
surface for a 2sec period with the mouse’s head declining. Latency to fall from the screen 
was recorded, with a 2min time limit for each trial.  
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Mice were subject to a rotarod test to evaluate motor coordination and balance. 
Each animal was placed on the rotarod after which speed was adjusted to 3 rpm. The 
latency to fall off the rotarod within this time period was recorded for fixed speed. 
Animals were also tested for their latency to fall off at accelerated speeds going from 4 to 
40 rpm in 5mins.  
Animals were tested for each experiment 3 times with an inter-trial interval of 
approximately 30 min for each animal and mean of 3 trials was used to plot the graphs.  
Transmission Electron Microscopy: Mice were anesthetized and perfused with a solution 
of 2.5 % glutaraldehyde in 0.05 M Sodium Phosphate buffer, pH 7.2. The brain was 
extracted and incubated in 2.5 % glutaraldehyde in 0.05 M Cacodylate buffer overnight at 
4°C. It was sectioned into 1 mm thick sections, rinsed twice in the same buffer and post-
fixed with 1 % osmium tetroxide for 1h at room temperature.  Sections were washed in 
DH2O (heavy water) for 20 mins at 4°C and then dehydrated in graded ethanol series of 
20% increments, before two changes in 100 % ethanol.  Sections were infiltrated with 
two changes of 100% Propylene Oxide and then with a 50%/50% propylene oxide / SPI-
Pon 812 resin mixture overnight.  After three changes of fresh 100 % SPI-Pon 812 resin, 
sections were polymerized at 68°C in plastic capsules. Regions of interest were cut out 
and thick-sectioned for toluidine blue. Chosen regions were reoriented and approximately 
70nm thin sections were placed on copper support grids and contrasted with Lead citrate 
and Uranyl acetate.  Sections were examined using the FEI Tecani 12 BT with 80Kv 
accelerating voltage, and images were captured using a Gatan TEM CCD camera. 
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Total Lipid Isolation: Total brain lipids were evaluated from the frozen cerebrum, 
cerebellum, and medulla of P25 and P60 WT, CD/PBS, and CD/rAAV9 mice. Tissues 
were homogenized in water and lyophilized for 24 hr.   After desiccation, the dried tissue 
was weighed, rehydrated in water (0.05 ml), and lipids were extracted overnight in 
CHCl3:CH3OH (1:1; v/v) according to standard procedures (Baek et al., 2009; Hauser et 
al., 2004).  Lipids were further separated into a neutral (F1) and acidic/ganglioside (F2) 
fraction via ion exchange chromatography over a Sephadex column (Baek et al., 2009; 
Macala et al., 1983). Neutral lipids and cholesterol were eluted with a 
CHCl3:CH3OH:dH2O (30:60:8; v/v/v) solution, while acidic phospholipids and 
gangliosides were eluted with a CHCl3:CH3OH:0.8M CH3COONa (30:60:8; v/v/v) 
solution.  Gangliosides were separated from acidic phospholipids by Folch partitioning, 
base treated, and desalted as previously described (Folch et al., 1957).  Neutral lipids 
were dried by rotary evaporation and resuspended in 10 ml CHCl3:CH3OH (2:1; v/v).    
Sialic acid quantification: Total ganglioside content was quantified before and after 
desalting using the resorcinol assay (Hauser et al., 2004; Svennerholm, 1957).  Three 
aliquots of each ganglioside sample were dried under vacuum. Resorcinol reagent: water 
(1:1 v/v) solution (resorcinol reagent – HCl:0.2M resorcinol: DH2O: 0.1 M CuSO4, 
40:5:5:0.125 v/v/v/v) was added to each sample, followed by submersion in a boiling 
water bath for 15 min.  After cooling on ice, the reaction was stopped with butyl acetate: 
N-butanol (85:15; v/v) (Seyfried et al., 1978).  Each sample was vortexed and centrifuged 
at 700x g for 2 min.  The absorbance of the upper aqueous layer was recorded at 580 nm 
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using a Shimadzu UV-1601 Spectrophotometer (Shimadzu, Torrance, CA).  Sialic Acid 
values were fit to a standard curve using N-acetylneuraminic acid as a standard.  
Thin-Layer Chromatography: All lipids were analyzed by high-performance thin-layer 
chromatography (HPTLC) as previously described (Kasperzyk et al., 2004; Macala et al., 
1983). Neutral and acidic lipids were spotted using a Camag Linomat II auto-TLC spotter 
(Camag Scientific Inc., Wilmington, NC, USA.). The amount of neutral lipid spotted 
corresponded to 70μg dry weight. The plate was developed in solvent system I to 4.5 cm 
which contained Chloroform:Methanol: acetic acid: formic acid:H2O (70:30:12:4:2 by 
vol.) and solvent system II to the top which contain hexane: isopropyl ether: acetic acid 
(65:35:2 by vol.). The amount of acidic lipid spotted corresponded to 200 μg of dry 
weight and was developed in solvent system I to 6.0 cm and in solvent II to the top.  
Bands for both neutral lipids and acidic lipids were visualized by charring with 3 % 
cupric acetate in 8% phosphoric acid solution in an oven at 160°C for 7 min. 
Gangliosides were spotted based on 1.5 μg of sialic acid and were developed in 
chloroform:methanol:0.02% calcium chloride (C:M:.02%CaCl2).  Individual lipid bands 
were scanned using Camag TLC Scanner 4 and the concentration of cerebrosides and 
sulfatides were calculated from a standard curve (Baek et al., 2009). The total brain 
ganglioside distribution was normalized to 100 % and the percentage distribution values 
were used to calculate sialic acid concentration of GM1. 
X-ray Diffraction Analysis: X-ray diffraction was performed as described (Avila et al., 
2005). Briefly, optic nerves and spinal cords were dissected from mice sacrificed using 
isoflurane. Optic nerves and sagitally bisected segments of cervical spinal cord were 
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maintained in physiological saline (154mM NaCl, 5mM phosphate, pH 7.4) and loaded 
into thin-walled, quartz capillary tubes which were then filled with saline and sealed with 
wax and enamel. X-ray diffraction experiments were carried out using nickel-filtered, 
single-mirror focused CuKα radiation from a fine-line source on a 3.0 kW Rigaku X-ray 
generator operated at 40 kV by 10 mA. Exposure times were 30 min. Diffraction patterns 
were collected using a linear, position-sensitive detector (Molecular Metrology, Inc., 
Northampton, MA) and analyzed using PeakFit (Jandel Scientific, San Rafael, CA). 
Myelin period was calculated from the positions of the intensity maxima in the 
diffraction patterns. The relative amount of myelin in each sample was calculated by 
measuring the total integrated intensity of all maxima over background, excluding small-
angle scatter around the beam stop and wide-angle scatter. 
Statistical Analyses: Statistical calculations included Log rank Mantel Cox test for the 
survival table and one way ANOVA followed by Tukey’s Multiple Comparison test for 
all other experiments. *P < 0.05; **P < 0.01; ***P < 0.001, NS not significant. 
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Results 
AspA deficiency causes progressive neuropathy and retinopathy in early postnatal mice  
Histologic examination of the brains from wild-type (WT) and CD mice (n = 4 
each) at P0, P6, P13, P20, and P25 showed appearance of vacuoles in the CNS of CD but 
not WT mice at P13, which gradually increased in size and number with age. 
Neurodegeneration was considered severe by P25 [Figure 3.1a] with afflicted mice dying 
shortly afterwards. Quantification of intact tissue areas showed progressive pathology in 
the striatum, thalamus and brainstem [Figure 3.1b], suggesting that AspA helps to 
maintain CNS integrity.  
After full eye opening at P16, WT and CD mice (n = 4) were evaluated for retinal 
response to light flickers by scotopic electroretinography (ERG) at P16, P20, P23, and 
P27. The ERG trace is produced by the electrophysiological action of the retinal cells and 
typically consists of a- and b-waves that indicate photoreceptor and glial cell activities 
respectively. Sequential ERGs revealed progressive reductions in retinal responses of CD 
mice [Figure 3.1c] indicating the importance of AspA for maintaining visual acuity. 
IV injections of rAAV9hAspA and rAAV9hAspAmiRNA-BS reconstitute AspA in the 
CNS 
CD mice injected with rAAV9hAspA (CD/rAAV9) at P0 were killed at 3 months 
to evaluate brain AspA levels by western blot. AspA levels in the gene-corrected (GC)  
 
117 
 
 Figure 3.1 Progressive neuropathology and retinopathy in postnatal CD mice.  
(a) Representative images of hematoxyline and eosin (H&E) stained brain sections (n = 
4). Bars: 4.8 mm. (b) Semiquantitative analyses of neuropathology normalized to WT 
animals using Image J. Ob, olfactory bulb; Cx, cortex; Hp, hippocampus; St, striatum; 
Th, thalamus; Ce, cerebellum; BS, brain stem. (c) Scotopic ERGs of overnight dark-
adapted WT and CD mice (n = 4 each) to test the response of rods recorded as waveforms 
(μV) to flickers of light in increasing intensity called steps. CD, Canavan disease; ERG, 
electroretinography; WT, wild-type. 
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Figure 3.1 Progressive neuropathology and retinopathy in postnatal CD mice. 
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Figure 3.2 Enzymatic and metabolic correction of AspA deficiency by systemically 
delivered rAAV-mediated gene therapy in CD mice. (a) Western blot of brain 
homogenates from WT (P90), Het (P90), and CD mice treated with PBS (P27) or 
rAAVhAspA (P90). Loading control: GAPDH. (b) Aspartoacylase activity in brain 
homogenates of the study groups. (c) Persistent vector genomes (by quantitative PCR) 
and aspartoacylase expression (by western blot) in P90 CD/rAAV9hAspA and 
CD/rAAV9hAspAmiRBS. (d) Representative images of avidin-biotin-complex (ABC) 
stained brain sections. (e) Immunofluorescence images of brain sections from P90 WT 
and CD/rAAV9 for AspA (green) and neuronal marker, NeuN (red) and colocalization 
(yellow). Bars: 10 μm. (f) Representative MRS spectra of brain NAA levels in WT and 
CD/PBS mice at P26 (n = 3 each) showing NAA peaks at 2.018 ppm. (g) Quantification 
of in vivo brain metabolite levels from the proton spectra as ratio to total creatine. Ins: 
inositol, tCho: total choline, tNAA: total NAA, tCr: total creatine, Glx: glutamate + 
glutamine. (h) Mass spectrometry of urine from P27 WT, Het and CD/PBS or 
CD/rAAV9 mice. WT, wild-type; Het, heterozygote; CD/PBS, CD/rAAV9, CD mice 
treated with PBS or rAAV9 respectively. CD, Canavan disease; MRS, magnetic 
resonance spectroscopy; NAA, N-acetyl aspartic acid; NS, not significant; PBS, 
phosphate-buffered saline; rAAV, recombinant adeno-associated virus. 
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Figure 3.2 Enzymatic and metabolic correction of AspA deficiency by systemically 
delivered rAAV-mediated gene therapy in CD mice. 
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mice were similar to age- matched phenotypically normal heterozygous (Het) mice 
[Figure 3.2a]. Protein levels depicted in the blot were typical of the trend observed, 
although there was significant variability in the level of protein expression among the 
different vector-treated animals. 
AspA enzyme activity (normalized to WT mice) in brain homogenates of GC 
mice were similar to Het mice (P > 0.05) [Figure 3.2b]. To reduce transduction in 
peripheral tissues such as liver, heart, and skeletal muscle by systemically delivered 
rAAV9 hAspA, a miRNA-regulated vector genome was designed for CNS-restricted 
gene transfer (Xie et al., 2012). Equal doses of rAAV9hAspA and rAAV9hAspA-(miR-
1BS)3-(miR-122BS)3 (i.e., rAAV9hAspAmiRBS) with three copies each of the miRNA-
BS specific to miR-1 and miR-122 (enriched in heart, skeletal muscle, and liver, 
respectively) were infused into CD mice at P0. Both vectors targeted brain, liver, heart, 
and muscle tissues equally; but the miRNA-regulated vector abolished AspA expression 
only in peripheral tissues not the brain [Figure 3.2c], establishing specificity of miRNA-
regulated therapeutic expression from rAAV. 
Immunohistochemistry illustrated similar numbers and distribution patterns but 
different staining intensities of AspA positive cells in the brains of WT and GC mice 
[Figure 3.2d]. Large vacuoles in CD mouse brain sections made detection of residual 
AspA difficult. Double immunofluorescence staining showed efficient neuronal AspA 
gene transfer by rAAV9 in the cortex, hippocampus, and thalamus in GC mice [Figure 
3.2e]. 
122 
 
Spectral peak integrals for total NAA (2.02 ppm) and total creatine (tCr, 3.05 
ppm) (Grodd et al., 1990; Matalon and Michals-Matalon, 2000) were determined by 
acquiring 1H 1H proton magnetic resonance spectroscopy data from live animals (n = 3). 
Abnormally high endogenous NAA levels were detected in CD mice relative to WT mice 
as expected (Matalon et al., 2000; Pioro et al., 1998) [Figure 3.2f]. Integrated values of 
NAA/creatine ratios were significantly different between WT (0.886 ± 0.03), and CD 
(2.63 ± 0.16) (P > 0.001); such values were reduced in GC mice (2.18 ± 0.64) [Figure 
3.2g]. N-acetylaspartic aciduria (excretion of NAA in the urine), a biomarker of CD 
(Matalon et al., 1988)  was significantly reduced in GC mice (P > 0.001) compared with 
CD mice [Figure 3.2h]. 
AspA gene therapy in CD mice alleviates neuropathology, cerebral edema, and 
retinopathy  
Hematoxylin and eosin stained coronal sections of brain and spinal cord from 
terminal stage (P27) CD and P90 GC mice were examined [Figure 3.3] and quantified 
[Figure 3.3b] for neuropathology. Our data suggest significant improvements in all 
regions of spinal cord and most regions of the brain. 
T2-weighted magnetic resonance imaging was used to detect cerebral edema 
(Matalon et al., 1993) in WT (P60, n = 3), CD (P27, n = 3), and GC animals treated with 
rAAV9hAspA and rAAV9hAspA-miRBS (P60 and P365, n = 3). CD brains exhibited 
widespread high signal intensities, indicating water accumulation particularly in the 
thalamus (mainly midbrain) and brainstem [Figure 3.3c], which mirror conditions in 
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patients (Matalon, 1997); but T2-weighted hyperintensity in both groups of GC mice was 
generally reduced [Figure 3.3c]. More importantly, reduction of edema seemed to be 
sustained in P0-treated GC mice for 1 year [Figure 3.3c]; however, NAA levels in 
rAAV9hAspA-treated mice were lower than in AAV9hAspAmiRBS–injected mice 
[Figure 3.3d]. Thus, single rAAV injections were able to partially, but sustainably, 
relieve cerebral edema.  
Retinal responses of GC mice were similar to those of age-matched WT mice even after 1 
year, although amplitudes of both a- and b-waves were lower, suggesting partial but 
sustained correction of visual acuities [Figure 3.3e].  
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Figure 3.3 Intravenous (IV) gene therapy using rAAV9 mitigates neuropathology, 
reduces water accumulation in the brain and improves visual acuity. (a) 
Representative images from hematoxylin and eosin (H&E) stained paraffin sections (n = 
4 for each group). (b) Quantification of neuropathology by ImageJ. Ob, olfactory bulb; 
Cx, cortex; Hp, hippocampus; St, striatum; Th, thalamus; Ce, cerebellum; BS, brain stem; 
CSP cervical spinal cord; TSP, thoracic spinal cord; LSP, lumbar spinal cord. (c) 
Representative T2-weighted magnetic resonance imaging images showing water 
accumulation (white) in P25, CD/PBS; P60, P365 GC; and WT animals. (d) 
Quantification of MRS data for metabolites in brains of mice injected with rAAV9 or 
rAAV9BS at P0 at age P90. (e) Scotopic ERG of WT, CD/PBS and CD/rAAV9 at P25 
and P365, respectively, to test visual acuity. WT, wild-type; CD/PBS, CD/rAAV9, CD 
mice treated with PBS or rAAV9 respectively. CD, Canavan disease; ERG, 
electroretinography; MRS, magnetic resonance spectroscopy; NS, not significant; PBS, 
phosphate-buffered saline; rAAV, recombinant adeno-associated virus. 
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Figure 3.3 Intravenous (IV) gene therapy using rAAV9 mitigates neuropathology, 
reduces water accumulation in the brain and improves visual acuity 
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Systemic and CNS-restricted AspA gene therapy by different rAAVs is therapeutic for 
CD mice 
In addition to rAAV9, two other rAAVs (i.e., rAAVrh.8 and rh.10) were selected 
for this proof-of-concept gene therapy study in CD mice. Therapeutic efficacies of these 
vectors (i.e., rAAV9hAspA, rAAV9hAspA-miRBS, rAAVrh.8hAspA or 
rAAVrh.10hAspA) were evaluated in CD mice by comparison of growth, survival and 
negative geotaxis (all four vectors) as well as other motor functions (rAAV9hAspA and 
rAAV9hAspA-miRBS only) All these vectors were delivered intravenously at P0.  
Growth profiling showed that CD mice were phenotypically similar to WT 
littermates until P13 after which they steadily lost weight until their death [Figure 3.4a, 
inset]. Compared to rAAV9, GC mice treated with other vectors showed no significant 
differences in survival or growth [Figure 3.4a]. 
Since survival is an important criterion for therapeutic benefits, survival of >50 
GC mice was examined using the Kaplan–Meier curve [Figure 3.4b]. There was a 
uniform rescue of lethality with extended survival as long as 2 years for rAAV9- and 
rAAVrh.8-injected animals. Long-term study of rAAVrh.10 was initiated about 1 year 
later; the animals have survived well for 11 months thus far. The negative geotaxis test 
for early postnatal spatial locomotive behavior showed that GC mice but not CD mice 
performed similar to their WT littermates [Figure 3.4c]. CD/rAAV9 mice were compared 
with CD/ phosphate-buffered saline (PBS) mice at P27 and WT at P27, P90, and P180 to 
further evaluate motor functions. GC mice significantly improved in balance (P < 0.001) 
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[Figure 3.4d], and grip (P < 0.001) [Figure 3.4e] over CD mice at P27. Data from later 
timepoints revealed that the treatment fully and sustainably restored grip strength but not 
balancing abilities in GC mice [Figure 3.4 d & e]. GC animals performed significantly 
better than CD mice on the rotarod at P27 [Figure 3.4 f & g] but were significantly 
behind WT mice at later timepoints [Figure 3.4 f & g]. The GC mice that received the 
miRNA-regulated vector performed similar to rAAV9hAspAtreated mice in the fixed 
speed rotarod test but not in balance (P< 0.001), inverted screen (P < 0.05) and 
accelerated rotarod (P <  0.01) tests at P90 (Figure 4h). We noticed variability in the 
performance of P1 treated mice on the inverted screen and balance beam in later 
generations of CD mice. This suggests that genetic modifiers in the Sv129 background 
strain may alter the penetrance of the gene knockout, as has been observed with other 
gene knockouts [Flotte, personal communication]. Overall, our data suggest that IV gene 
therapy can largely restore motor functions of CD mice. 
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Figure 3.4 Intravenous (IV) gene therapy using novel rAAVs improves growth 
profile, rescues early lethality and corrects motor function defects of CD mice. (a) 
Weight of animals at 2-week intervals plotted as a function of time. Early growth rate 
was assessed by weights at 2-day intervals for the first month (inset). (b) Kaplan–Meier 
survival curves for groups treated with different vectors at P0 (“closed circles” = WT, 
“closed squares” = CD/PBS, “closed triangles” = CD/rAAV9, “closed up-side down 
triangles” = CD/rAAV9mirBS, “closed diamonds” = CD/rAAVrh.8, and “closed 
hexagon” = CD/rAAVrh.10, respectively). (c) Negative geotaxis test at intervals of 1 day 
from P7 (day 8) to P17 (day 16). Motor functions of study groups were tested at P27, 
P90, and P180 based on their performance on the (d) balance beam, (e) inverted screen 
and rotarod moving at (f) fixed speed (3 rpm) and (g) accelerated speed (4–40 rpm in 5 
minutes). The same tests were performed on (h) P90 CD/rAAV9 and CD/rAAV9mirBS. 
WT, wild-type; CD/PBS, CD/rAAV9, CD/rAAV9mirBS, CD/rAAVrh.8, and 
CD/rAAVrh.10: CD mice treated with PBS, rAAV9hAspA, rAAV9hAspA-mirBS, 
rAAVrh.8hAspA, and rAAVrh.10hAspA at P0, respectively. CD, Canavan disease; NS, 
not significant; PBS, phosphate-buffered saline; rAAV, recombinant adeno-associated 
virus. 
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Figure 3.4 Intravenous (IV) gene therapy using novel rAAVs improves growth 
profile, rescues early lethality and corrects motor function defects of CD mice. 
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Figure 3.5 Intravenous (IV) gene therapy with rAAVs as late as P20 improves 
growth profile, rescues early lethality and corrects motor function defects of CD 
mice. (a) Kaplan–Meier survival curves for all groups treated with different vectors at P0. 
(b) Weight of animals at 2-week intervals plotted as a function of time. (c) Early growth 
rate assessed by weights at 2-day intervals for the first month. (d) Negative geotaxis test 
at intervals of 1 day from P7 (day 8) to P17 (day 16). Motor functions of study groups 
were tested at P90 based on their performance on the (e) balance beam, (f) inverted 
screen and rotarod moving at (g) fixed speed (3 rpm) and (h) accelerated speed (4–40 
rpm in 5 minutes). WT, wild-type; CD/PBS, CD/P0, CD/P6, CD/P13, and CD/P20: CD 
mice treated with PBS and rAAV9hAspA at P0, P6, P13 and P20 respectively.  
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Figure 3.5 Intravenous (IV) gene therapy with rAAVs as late as P20 improves 
growth profile, rescues early lethality and corrects motor function defects of CD 
mice
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Figure 3.6 Intravenous (IV) gene therapy using rAAV9 improves myelin synthesis 
and partially corrects lipid profile of myelin in CD mice. (a) Electron microscopy of 
the motor cortex of P27 age-matched mice (n = 3 for each cohort). Bar: 2 μm. Inset: 
higher magnification. Black arrows: unmyelinated axons; white arrows: myelin sheath. 
(b) G ratios of myelinated axons calculated from toluidine blue stained sections of the 
cortex using ImageJ. (c) High-performance thin-layer chromatography of gangliosides in 
cerebrum, cerebellum, and medulla of different mouse groups (n = 3 for each group). 
Lower panel: quantification of the plate. (d) Quantification of the high-performance thin-
layer chromatography plate. 
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Figure 3.6 Intravenous (IV) gene therapy using rAAV9 improves myelin synthesis 
and partially corrects lipid profile of myelin in CD mice.  
 
134 
 
rAAV-mediated intravascular AspA gene delivery to the CNS as late as P20 is 
therapeutic 
 To define a therapeutic window, CD mice were systemically injected with only 
rAAV9hAspA at P0, P6, P13, and P20 (n = 6 each). IV injections at all the timepoints 
resulted in 100% rescue of early lethality, extended survival [Figure 3.5a] and improved 
growth profiles [Figure 3.5 b & c]. There was significant variability in the performance of 
the facial injection, as judged by direct observation of blanching of the vein during 
injection.  A number of the animals in which poor blanching was observed died within 28 
days, in a manner similar to the non-injected animals.  While the number of suboptimal 
injections decreased over time, certain animals experienced early mortality (less than 28 
days) even with what appeared to be robust blanching of the vein.  Because of this 
variability in the injection procedure, all vector-treated animals dying prior to 28 days 
were excluded. Tests for negative geotaxis [Figure 3.5d], balance [Figure 3.5e], grip 
strength [Figure 5f], and abilities to stay on the rotarod [Figure 3.5g & h] at P90 clearly 
showed that early intervention was more beneficial to the diseased animals, although 
injections as late as P20 were sufficient to completely rescue early lethality and partially 
restore growth and mobility [Figure 3.5]. 
Hypomyelination and abnormal brain lipid profiles are improved by IV gene therapy 
 Electron microscopy on the brain cortices of P25 mice (n = 3 each) showed 
demyelination around neurons in CD/PBS mice (Adachi et al., 1972; Beaudet, 2001). In 
contrast, the myelin sheaths in GC mice were similar to those of WT in most of analyzed 
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regions [Figure 3.6a]. A highly reliable structural index of optimal myelination is the 
ratio of inner axonal diameter to the outer diameter of the myelin sheath known as the g-
ratio (Chomiak and Hu, 2009). A higher ratio indicates less myelin and altered 
conduction capabilities. A semiquantitative comparison of the g ratios between mouse 
groups further supports the crucial role of AspA in maintaining axonal integrity and 
myelination [Figure 3.6b].Neurochemistry in CD and GC mice was studied by 
quantitative high-performance thin-layer chromatography (HPTLC) on 21 brain lipids in 
the cerebrum, cerebellum and medulla collected from WT (P25 and P60), CD (P25 only), 
and GC (treated at P0, analyzed at P25 and P60) mice (n = 3 each). Compared with WT 
mice, at P25, the total concentration of gangliosides was lower in the cerebrum and 
cerebellum of CD mice whereas gene therapy largely corrected this defect [Figure 3.6 c 
& d]. Concentrations of neuronal-enriched gangliosides (GD1a, GT1b, and GQ1b) at P25 
were significantly lower in CD mice than the WT mice but were largely corrected in the 
GC mice [Figure 3.6c, Table 3.1]. Although the concentrations of all major gangliosides 
were lower in the GC mice compared with WT mice, none of these reductions was 
significant except for GM1 in the cerebrum [Table 3.1]. CD mice had significantly lower 
cholesterol content in the cerebrum and medulla compared with WT mice. Though 
largely corrected in the GC mice at P25, significant reduction was still seen in the 
cerebrum and cerebellum of GC mice at P60 [Figure 3.6c, Table 3.1]. 
 It is noteworthy that deficiencies in cerebrosides and sulfatides were not 
completely corrected in the GC mice at either age [Table 3.2]. Cerebrosides and 
sulfatides migrate as double bands on the HPTLC due to differences in their hydroxyl 
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fatty acid content [ Figure 3.7 a & b] (Baek et al., 2009). The slower (lower, L) migrating 
band mostly contains short-chain hydroxylated fatty acids; whereas, the faster (upper, U) 
band mostly contains longer chain nonhydroxylated fatty acids(Baek et al., 2009). Our 
HPTLC data [Table 3.2] suggests that the increased L/U (lower/upper band) ratio in the 
CD and GC mice is due to a greater deficiency of the non-hydroxylated fatty acids. 
Myelin structure in optic nerves and spinal cords from WT (n = 4), CD/PBS (n = 
5), and CD/rAAV9 mice at P26 (n = 4) [Figure 3.8] was examined using X-ray 
diffraction to quantify structural parameters like myelin period and relative amount of 
myelin(Agrawal et al., 2009; Avila et al., 2005). Diffraction from both tissues yielded 
strong intensity maxima, indicating the presence of significant amounts of multilamellar 
myelin [Figure 3.8a & b]. Each group displayed similar relative amounts of myelin 
[Figure 3.8c & d]. Myelin period is defined as the distance between subsequent pairs of 
bilayers. Any aberration in periodicity indicates inadequate insulation and subsequent 
neurological impairment. Spinal cords from CD/rAAV9 mice displayed a significantly 
higher myelin period (160.3 ± 0.5 Å) (P < 0.04) compared with CD/PBS mice (159.1 ± 
0.8 Å). Optic nerves, CD/rAAV9 samples had a significantly higher period (157.7 ± 0.7 
Å) than WT (156.6 ± 0.7 Å) (P < 0.006) [Figure 3.8c & d]. Other differences in myelin 
period and amount were not statistically significant. The I2/I4 ratio is a measure of the 
relative intensity of the 2nd order X-ray reflection over the 4th order reflections. 
Comparison of the I2/I4 ratios revealed a statistically significant decrease in the 
CD/rAAV9 mice compared with WT [Figure 3.8e & f], indicating a small change in 
membrane structure. 
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Table 3.1 Regional brain ganglioside distribution in 25 day old normal (WT), 
Canavan disease (CD), and CD mice treated with AAV gene therapy (GC) and 
60day old normal (WT) and CD mice corrected by gene therapy (GC).
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Figure 3.7 HPTLC of neutral and acidic lipids in cerebrum, cerebellum, and 
medulla of WT, CD/PBS, and CD/rAAV9. HPTLC of (a) neutral and (b) acidic lipids 
in cerebrum, cerebellum, and medulla of WT, CD/PBS, and CD/rAAV9 mice. The 
amount of neutral and acidic lipids spotted per lane was equivalent to approximately 70 
µg and 200 µg brain dry weight respectively. The plate was developed to a height of 4.5 
cm for neutral lipids and 6 cm for acidic lipids The bands were visualized by charring 
with 3% cupric acetate in 8% phosphoric acid solution. WT, wildtype; CD/PBS, GC; CD 
mice treated with rAAV respectively. Statistical tests include one way ANOVA followed 
by Tukey’s Multiple Comparison Test. *P < 0.05; **P < 0.01; ***P < 0.001, NS not 
significant. 
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Figure 3.7 HPTLC of (a) neutral and (b) acidic lipids in cerebrum, cerebellum, and 
medulla of WT, CD/PBS, and CD/rAAV9 mice. 
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Table 3.2 Molecular species composition of cerebrosides and sulfatides in normal 
(WT), Canavan disease (CD) and CD mice treated with AAV gene therapy (GC). 
Brain from mice of different ages was isolated, homogenized and subject to High 
Performance Thin layer chromatography for isolation of molecular species of 
cerebrosides and sulfatides. 
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 Table 3.2 Molecular species composition of cerebrosides and sulfatides in normal 
(WT), Canavan disease (CD) and CD mice treated with AAV gene therapy (GC). 
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Figure 3.8 X-ray diffraction patterns collected from optic nerves and spinal cords 
isolated from P26 mice. X-ray diffraction patterns collected from (a) optic nerves and 
(b) spinal cords isolated from P26 WT (n = 4), CD/PBS (n = 5), and CD/rAAV9 (n = 4) 
mice. The spectra, which represent averaged patterns from one spinal cord or two optic 
nerves from each animal in the group, have been offset along the y-axis for clarity. The 
Bragg orders for each reflection are indicated by numerals above their maxima. Scatter 
plots of M/(M+B) versus myelin period for (c) optic nerves and (d) spinal cords from 
WT, CD/PBS, and CD/rAAV9 mice. Error bars represent ±1 standard deviation centered 
on the average for each group. Comparison of the relative intensities of Bragg reflections 
measured from (e) optic nerves and (F) spinal cords among groups. Relative intensities 
are presented as the intensity of the 2nd order Bragg reflection divided by that of the 4th 
order reflection (I2/I4), normalized by myelin period. *P < 0.05; **P < 0.01 (Student’s t-
test). 
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Figure 3.8 X-ray diffraction patterns collected from optic nerves and spinal cords 
isolated from P26. 
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Discussion 
Our study aims to develop efficacious therapeutics for CD using the AspA−/− KO 
mouse model and systemically delivered rAAVs for CNS-targeted AspA gene therapy as 
well as address off-target transgene expression in peripheral tissues. The AspA−/− mouse 
model in SV129/Ev background (Matalon et al., 2000) recapitulates the severest form of 
CD. Animals show progressive neuropathology and retinopathy, severe developmental 
delay, difficulties in mobility and whole body tremors around P19, which gradually 
worsens until their death around P27 [Figures 3.1 & 3.4a] making them a stringent 
preclinical model to study the molecular etiology of AspA deficiency and evaluate 
efficacious therapeutics, primarily based on the rescue of early lethality. Our study 
clearly demonstrated the feasibility of completely rescuing the early lethality, slowing 
down the disease progression, and extending the survival of CD mice [Figure 3.4b].  
Our findings address several critical issues in systemically delivered CNS gene 
therapy. First, IV injections of rAAVrh.8 and rAAVrh.10 to CD mice at P0 are 
therapeutically equivalent to rAAV9, significantly improving their early motor function 
and growth, and effectively rescuing early lethality, which expands options in the existing 
rAAV repertoire to select serologically suitable vectors for patient populations. Our data 
also provide the first evidence of harnessing endogenous miRNA to regulate therapeutic 
expression of rAAV tissue specifically, which is shown to be safe, not disturbing 
homeostasis or function of endogenous miRNAs (Xie et al., 2010). In addition, the 
success of IV gene therapy as late as P20 in CD mice represent a clinically relevant 
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advance from the documented therapeutic benefit at P10 in a mouse model for spinal 
muscular atrophy (Foust et al., 2010). However, we did observe reduced mobility in the 
later treated animals [Figure 3.4d–g], which indicates that early intervention is 
therapeutically more beneficial, echoing the results of a recently concluded CD gene 
therapy study on patients (Leone et al., 2012). 
Robust neuronal transduction in GC mice [Figure 3.2e] suggested that rAAV9 
delivered AspA may improve myelin structures by hydrolyzing NAA at its source but 
may not help myelination by oligodendrocytes. Our detection of aspartoacylase-
expressing neurons in the WT animals also differs from published data (Madhavarao et 
al., 2003; Madhavarao et al., 2004) but would explain the widespread activity detected in 
cerebral hemispheres [Figure 3.2d], although we cannot discount possible cross-reactivity 
of our AspA antibody with amidohydrolase I that has only 7% reactivity toward NAA 
(Goldstein, 1976; Mehta and Namboodiri, 1995). 
Improved motor functions [Figures 3.4d–h & 3.5e–h] might result from 
reconstituted AspA and mitigated neuropathology in the pyramidal nuclei of the 
hindbrain and spinal cord of treated mice [Figure 3.3 a & b]. However, we did see partial 
hind limb paralyses with dragging of hind limbs and decline in mobility starting around 8 
months post-injection [Video 3.4], although the animals still have intact righting reflexes, 
move around and eat with no obvious weight losses. One possible cause for the late-onset 
motor dysfunctions could be due to a gradual loss of rAAV-mediated AspA expression as 
a consequence of glial cell transduction and regeneration. Around 14 months, the animals 
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started showing infrequent and brief seizures. Readministration of serologically different 
rAAVs by a different route may help to sustain correction of myelin neurochemistry and 
motor function as CNS-directed rAAV gene. 
 Lipid abnormalities for myelin-enriched cerebrosides in CD mice were largely 
similar to those in the tremor rat model of CD (Saher et al., 2005; Wang et al., 2009). 
Since cholesterol is a major component of the myelin sheath, its reduction can be 
attributed to defects in myelin content (Saher et al., 2005). CNS-targeted AspA gene 
transfer by rAAVs appears to correct abnormalities in ganglioside and cholesterol levels 
but not the myelin-specific (cerebrosides) or myelin-enriched (sulfatides and GM1 
ganglioside) lipids [Figure 3.6d & Table 3.2). The subtle differences in electron density 
distribution within the myelin sheath detected among all groups [Figure 3.8] are also 
consistent with altered lipid profiles. Further studies are warranted to compare the 
physiochemical properties and biophysical structures of myelin in the CD and GC mice. 
X-ray diffraction analysis, however, did not detect differences in relative amount of 
myelin between WT, CD, and GC mice. It is unclear whether this is a result of changes in 
axon diameter, lower total scatter from affected animals or region-specific differences in 
optic nerves and spinal cords. In addition, the dramatic loss of vision in CD mice [Figure 
3.1c] might arise from demyelination of optic nerves, retinal degeneration, and 
pathological changes in cell types responsible for visual acuity, or all of the above. 
When translated into human applications, the vector dose regimen used in our 
study is ~2 × 1014 vector genomes/kg. Even though similar doses have recently been 
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approved for systemic delivery of rAAV9 to pediatric patients of spinal muscular atrophy 
(2012); lower doses would reflect a more favorable risk-to-benefit ratio clinically and 
reduced vector manufacturing burden.  
In conclusion, our study demonstrates the crucial role of AspA in myelination and 
early neurodevelopment as well as the feasibility of treating CD by CNS-targeted gene 
therapy using systemically delivered rAAVs. A more comprehensive comparison of three 
leading vectors (i.e., rAAV9, rAAVrh.8 and rAAVrh.10) in CD mice may be warranted 
to select a clinical candidate vector. Afterwards, a formal toxicology, safety and 
biodistribution study of the clinical candidate vector in nonhuman primates may 
constitute a critical path leading to human clinical applications for gene therapy of CD 
and other untreatable CNS diseases. 
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CHAPTER IV: CNS-RESTRICTED GENE DELIVERY USING RAAVS 
RESCUES LETHALITY BUT NOT MOBILITY DEFECTS SUGGESTING 
PERIPHERAL TISSUE INVOLVEMENT AND INFLAMMATION-MEDIATED 
PATHOLOGY IN CD MICE 
 
The following chapter contains the manuscript: 
Ahmed SS, Schattgen S, Sikoglu ME, Su Q, Hampton TG., Fitzgerald K, Matalon R, 
Gao G. CNS-restricted gene delivery using rAAVs rescues lethality but not mobility 
defects suggesting peripheral tissue involvement and inflammation-mediated pathology 
in CD mice (manuscript under preparation) 
The study was devised and results were interpreted by me under the supervision of Dr 
Gao. All experiments except for the ones listed below have been performed by me and 
the manuscript was prepared by me and Dr Gao. Figure 4.6 c, d were contributed by 
Stefan Schattgen. Figure 4.1e was prepared by Dr Elif Sikoglu, Figure 4.5e upper panel 
was contributed by Dr Thomas Hampton. Dr Matalon kindly provided the mice. The 
manuscript was prepared by me and corrected by Dr Gao.  
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CHAPTER IV: CNS-restricted gene delivery using rAAVs rescues lethality but not 
mobility defects suggesting peripheral tissue involvement and inflammation-
mediated pathology in CD mice 
Introduction 
Progressive spongy white matter degeneration and edema in the brain are 
hallmarks of a rare fatal pediatric leukodystrophy- Canavan disease (CD). Clinical 
symptoms include low muscle tone, blindness, severe motor retardation and premature 
death (Traeger and Rapin, 1998). The disease occurs due to autosomal recessive 
mutations in the enzyme aspartoacylase (AspA) (EC 3.5.1.15) that metabolizes N-acetyl 
aspartic acid (NAA) to yield acetate for myelination (Birnbaum et al., 1952 ; Kaul et al., 
1993; Matalon et al., 1988; Mehta and Namboodiri, 1995). Aspartoacylase is known to 
regulate lipid synthesis in the brain and its substrate NAA is the second-most abundant 
metabolite in the brain. NAA is produced by neurons and used by oligodendrocytes to 
coordinate their differentiation, energy production, and lipid synthesis (Namboodiri et al., 
2006). Absence of AspA leads to accumulation of NAA in the body and subsequent 
NAAduria that is a unique to CD (Matalon et al., 1988). NAA has been known to induce 
seizures and generate reactive oxygen species (Akimitsu et al., 2000; Pederzolli et al., 
2009); however, it has not been studied if the NAA accumulated in the absence of AspA 
cause the activation of immune cells that result in the spongy degeneration of the brain. 
Since CD is a monogenic neurodegenerative disease, use of recombinant adeno-
associated viruses (rAAVs) promises to be an attractive therapeutic option. Additionally 
modulation of serotype and the route of delivery can enhance transduction specificity. 
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The first bona-fide animal model to study the disease was the aspartoacylase knockout 
mouse (CD mouse) (Matalon et al., 2000). In the Sv129/Ev background, these mice have 
a very short perinatal lifespan (<4 wks) and recapitulate clinical symptoms of the severest 
manifestation of CD (Ahmed et al., 2013; Matalon et al., 2000). Hence, they are a 
stringent preclinical model to evaluate therapeutics primarily based on the rescue of early 
lethality (Ahmed et al., 2013). 
 Our previous study used systemically delivered rAAVs for CNS-directed AspA 
gene therapy in the CD mouse model, a stringent preclinical model for the congenital 
form of the disease (Ahmed et al., 2013). The therapy completely rescued early lethality, 
slowed disease progression and extended survival of CD mice. rAAVrh.8 and rAAVrh.10 
were found to be  therapeutically equivalent to rAAV9, thus, expanding options in the 
existing rAAV repertoire for selection of serologically suitable vectors for patient 
populations. The vector dose used in the CD mice would translate to ~2×1014
2012
 vector 
genomes/kg in humans. Even though similar doses have recently been approved for 
systemic delivery of rAAV9 to pediatric patients of spinal muscular atrophy ( ); 
lower doses would reflect a more favorable clinical risk-to-benefit ratio and reduce vector 
manufacturing burden.  
The intravenous delivery route allows for transduction of the whole body wherein 
only a small fraction gets in the brain justifying the large vector dosage.  To make lower 
doses more effective, vectors should be delivered into the CNS. Intraparenchymal 
injections have been the most widely used delivery routes for the Central Nervous 
System (CNS) allowing the direct targeting of a defined cell population (Leone et al., 
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2000). Though useful for region specific corrections, intraparenchymal injections are not 
suited for global CNS corrections since there is limited diffusion of the therapeutic from 
the injection site. To ensure global CNS delivery, use a lower dose of vector yet avoid 
unnecessary transduction of peripheral tissues, a promising avenue is the 
intracerebroventricular route of vector administration. The injections rely on the ability of 
rAAVs to cross the ependymal lining and enter the brain parenchyma from the cerebral 
ventricles within the first 24 hours of birth (Passini and Wolfe, 2001). Intraventricular 
injection of rAAVs at this age results in widespread transduction of neurons throughout 
the brain (Kim et al., 2014). Our previous studies and early reports on the abilities of 
rAAVs in mediating CNS transduction by intravascular delivery (Foust et al., 2009; 
Zhang et al., 2011) prompted us to compare the relative therapeutic abilities of these 
vectors in enhancing survival using intracerebroventricular delivery.  
 For gene therapy, we administered rAAV9, rAAVrh.8 and rAAVrh.10 carrying 
the human AspA gene intravascularly and intracerebroventricularly in CD mice at P0. 
Here, we demonstrate that a 50-fold lower dose than previously described for intravenous 
therapy (Ahmed et al., 2013) can still ameliorate disease symptoms; however, correction 
of the motor functions does not persist until the end of life. Additionally the previous 
study provided the first evidence of harnessing miRNA binding sites to regulate 
therapeutic expression of rAAV in a safe, tissue-specific manner without perturbing 
endogenous miRNA homeostasis or function (Ahmed et al., 2013; Xie et al., 2010). We 
also examined these animals and the ICV injected animals to study the role of AspA in 
peripheral tissues. We examined several morphological and functional aspects of 
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peripheral tissues of untreated mice and found that peripheral tissues do express AspA 
and its deficiency does cause pathology in these tissues. Our in-depth analyses of 
neuronal cell types help to understand their contribution to CD pathogenesis. Most 
importantly, our study demonstrates, for the first time, involvement of the immune 
system in response to accumulation of NAA and the importance of targeting peripheral 
tissues in CD.  
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Materials and Methods 
Viral production: All rAAV vectors were produced by transient transfection of 293 cells 
and CsCl gradient sedimentation as previously described (Sun et al., 2010). Vector 
preparations were titered by quantitative PCR, purity of vectors was assessed by 4–12 % 
SDS-acrylamide gel electrophoresis and silver staining (Invitrogen, Carlsbad, CA) and 
morphological integrity of virions was assessed by Transmission electron microscopy of 
negative stained recombinant AAV virions at Electron Microscopy Core, UMass Medical 
School, Worcester.   
Animal procedures: All animal procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC) of UMass Medical School. AspA
+/-
 Sv129/Ev mice 
littermates were bred using programmatic timing and newborn pups were dosed on P0. 
Vectors were injected in the facial vein of P0 pups at doses of 4X10
11
 GC/mouse and 
intracerebroventricularly at a dose of 2X10
10
Immunohistochemistry: Animals were anesthetized, transcardially perfused with 4% 
paraformaldehyde (v/v) in PBS. Whole carcasses were postfixed in fixative for 1 day. 
Organs were extracted, rinsed in PBS, and sagitally sectioned. One half was 
cryoprotected in 30 % sucrose (w/v) in PBS at 4°C, embedded in OCT compound 
(Sakura Finetek, Torrance, CA) and frozen in a dry ice/ethanol bath. 40μm floating 
sections of the entire brain were cut in a Cryostat (Thermo Microm HM 550) for 
immunostaining. The other half was processed for Hematoxylin and Eosin staining for 
 GC/mouse respectively. After the injection 
pups were cleaned, rubbed with bedding, and then returned to their cage. The dam was 
reintroduced after brief nose numbing using ethanol pads.  
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morphological studies.  
Floating sections were stained in 12-well plates. Sections were washed once in 
PBS for 5 mins, and incubated in blocking solution containing 0.05 % Tween-20 (v/v) 
(Fisher, Pittsburgh, PA), and 10 % goat serum (v/v) (Invitrogen) for 1 hour at room 
temperature. Sections were incubated with primary antibodies at 4°C overnight, washed 
twice in 0.05 % Tween-20 in PBS (PBST) for 15 mins each followed by incubation in 
appropriate secondary antibodies at room temperature for 1 hour. Sections were washed 
twice in PBST for 10 mins each before mounting on glass slides. Vectashield with 4,6-
diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) was used to mount all 
slides. Omission of either the primary or the secondary antibody in single-label 
experiments resulted in no labeling.  The primary antibodies used were as follows: mouse 
aspartoacylase (Abmart, New Jersey); mouse NeuN (MAB-377, clone A60; Millipore); 
rabbit NeuN (ABN-78, Millipore) and appropriate secondary antibodies from Invitrogen.  
For CD45 staining, the Dako dual link system was used. Briefly paraffin sections of the 
brain were deparaffinized and subject to heat-induced epitope retrieval (BD Retrievagen 
A). Slides were cooled and endogenous peroxidase was blocked using 3% (vol/vol) H2O2
Imaging and Image Analysis: Stained sections were examined using DM 5500B Upright 
microscope (Leica Microsystems, Wetzlar, Germany), and images were captured with 
Leica DFC365 FX high-sensitivity monochrome digital camera. Regions of interest were 
 
for 15 min. They were incubated with primary antibody for 1hr at room temperature, 
washed and incubated with the secondary antibodies. The slides were then counterstained 
with haematoxylin, dehydrated and mounted. 
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identified according to the mouse brain atlas. Z stack of images were taken with a 63X 
objective and 1.6X additional magnification for each channel and overlaid to obtain a 
multicolor image at 100.8X. Deconvolution was performed using Leica Application Suite 
Advanced Fluorescence software.  
Electrocardiography (ECG): ECGs were recorded non-invasively in conscious mice 
similar to a method described previously for mice (Chu et al., 2001). Briefly, mice were 
removed from their cages and positioned inside the ECGenie™ recording enclosure 
(Mouse Specifics, Inc., Boston, MA, USA). A pair of silver-chloride ECG electrodes 
were embedded in the floor of the enclosure and spaced to provide contact between the 
electrodes and animals’ paws. Since even modest handling may induce alterations in 
heart rate, each mouse was permitted to acclimatize for ∼10 min prior to collection of 
data. The signals were digitized at a sampling rate of 2000 samples/s. When mice were 
positioned such that a forepaw and hind paw were not uniquely in contact with one of the 
electrodes, the output from the amplifier was discarded. Only data from continuous 
recordings were used in the analyses. Each signal was analyzed using e-MOUSE™, 
which incorporates Fourier analyses and linear time-invariant digital filtering of 
frequencies below 3 Hz and above 100 Hz to minimize environmental signal 
disturbances. The software uses a peak detection algorithm to find the peak of the R-
waves and to calculate heart rate. Subsequently, determination of first and second 
derivatives and algebraic “if-then” search the ECG signals for probable P-wave peaks and 
onset and termination of QRS complexes. The end of the T-wave of each signal was 
defined as the point where the signal returned to the isoelectric line (the mean voltage 
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between the preceding P-wave and QRS interval). The QT intervals were rate corrected 
(QTc) by application of an equation recommended for rodent electrocardiography 
(Mitchell et al., 1998). The software plots its interpretation of P, Q, R, S, and T for each 
beat so that spurious data resulting from unfiltered noise or motion artifacts may be 
rejected. e-MOUSE™ then calculates the mean of the ECG time intervals for each set of 
waveforms.  
Electroretinography (ERG): Mice were dark-adapted overnight and anesthetized with 
100 mg/kg ketamine and 20 mg/kg xylazine in saline before testing. Both pupils were 
topically dilated with phenylephrine hydrochloride and 1% tropicamide, and mice were 
placed on a heated platform. Rod-dominated responses were elicited in the dark with 10 
μs flashes of white light (1.37×105
Western blot: Mice were sacrificed and their tissues were extracted and homogenized. 
Protein in equal quantities was loaded into a 12% Tris–HCl gel well (Bio-Rad 
Laboratories, CA) and transferred to a nitrocellulose membrane (Bio-Rad). The 
membrane was incubated in blocking buffer for 1hr followed by AspA polyclonal 
antibody overnight. After three washes in 0.1 % PBST, it was incubated with secondary 
antibodies conjugated to LI-COR IRDye for 1 hour at room temperature. After two 
washes with 0.1 % PBST signal was detected using the Odyssey Imager (LI-COR).  
 cd m−2) presented at intervals of 1 min in a Ganzfeld 
dome. ERGs were monitored simultaneously from both eyes with a silver wire loop 
electrode in contact with each cornea wetted with celluvisc containing Carboxy Methyl 
Cellulose Sodium 1%. 
Cell Titer Glo Assay:  Brains were dissected from 1-month-old female mice, washed, and 
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homogenized in Krebs-Ringers bicarbonate buffer (125mM NaCl, 1.4mM KCl, 20mM 
HEPES [pH 7.4], 5mM NaHCO3, 1.2mM MgSO4, 1.2mM KH2,PO4, 1mM CaCl2
Evans Blue injection: Vascular permeability was quantitatively evaluated by fluorescent 
detection of extravasated Evans blue dye. Briefly, 2% Evans blue dye in saline was 
injected intravenously as a BBB permeability tracer. Mice were deeply anesthetized with 
isofluorane and transcardially perfused until colorless perfusion fluid was obtained from 
the right atrium. Samples were weighted and homogenized in 10-fold volume of 50% 
trichloroacetic acid solution. The supernatant was obtained by centrifugation and diluted 
4-fold with ethanol. Fluorescence intensity was determined by a microplate fluorescence 
reader (excitation 620 nm and emission 680 nm). Calculations were based on the external 
standards dissolved in the same solvent. The amount of extravasated Evans blue dye was 
quantified as micrograms per tissue. 
) 
containing 1% BSA. Protein concentrations were determined using the BCA assay 
(Pierce). 50μg of brain lysate was used to measure ATP concentration using the 
CellTiter-Glo Luminescent Cell Viability kit (Promega) in a 96-well format and assayed 
using manufacturer’s instructions. To measure the recovery of ATP from brain lysates, 
known amounts of ATP were used to measure ATP bioluminescence using the CellTiter-
Glo method as above. The recovery of ATP was calculated from these values. 
Macrophage stimulation: Immortalized C57BL/6 macrophages were seeded in 6-well 
plates at 2 x 106 cells/well one day prior to stimulation. Cells were stimulated with 200 
ng/mL LPS or 1, 10, and 100 uM NAA overnight.  RNA was purified using an RNeasy 
kit (Qiagen) 
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qRT-PCR analysis: RNA was extracted using Trizol (Invitrogen), according to 
manufacturer's instructions. Total RNA (0.5–1μg) was reverse-transcribed (Reverse 
Transcriptase, Applied Biosystems). Quantitative PCR reactions were performed in 
triplicate with 0.3 μM gene-specific primer pairs using the GoTaq qPCR master mix 
(Promega) in a StepOne Plus Real-time PCR instrument (Applied Biosystems). 
Flow cytometry and Splenocyte proliferation assay: Spleen and thymus were crushed 
with frosted glass slides, red blood cell lysis performed, and resulting suspension strained 
through 70 uM cell strainer (BD Biosciences) to make single cell suspensions. For 
splenocyte proliferation assays, cells were labeled with 5 uM CFSE for 15 minutes prior 
to plating in 96-well plate coated with 10 ug/mL anti-CD3e and soluble anti-CD28 added 
at 1 ug/mL.  Cells were allowed to proliferate for 5 days before surface staining. Prior to 
staining, Fc receptors were blocked using supernatant from 2.4G2 hybridoma cells (anti-
CD16/32). Cells were stained using anti-TCRb-PerCP-Cy5.5, anti-CD19-PerCP-Cy5.5, 
anti-B220-AlexaFluor 488, anti-CD11b-FITC, anti-CD11c-eFluor 450, anti-Ly6G-PE-
Cy7, anti-Ly6C-APC, anti-NK1.1-APC, anti-CD3e-PerCP-Cy5.5, anti-FoxP3-eFluor450, 
(eBioscience), anti-CD45-V500, anti-CD8a-PE (BD Biosciences), anti-F4/80-PerCP-
Cy5.5, and anti-CD25-APC (Tonbo Bioscience). Data acquisition was performed using a 
4-laser LSRII (BD Biosciences). Analysis was performed using FlowJo analysis software 
(TreeStar).  
Genome copy number: rAAV genomes were quantified in 10ng of genomic DNA 
extracted from mouse tissues using the QIAamp DNA mini kit for quantitative detection 
of vector genome copies by Taqman® probes (Applied Biosystems) with a single-copy 
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endogenous GAPDH gene) as the diploid cell number reference. The Taqman® real-time 
PCR kit was run with primer sets which amplified regions of the nRBG poly A (Probe, 
6FAM-ATG AAG CCC CTT GAG CAT CTG ACT TCT-TAMRA; Fwd, GCC AAA 
AAT TAT GGG GAC AT; Rev, ATT CCA ACA CAC TAT TGC AAT G). The 
sensitivity of the assay was 10 copies/cell.  
Assays for serum ALT and AST levels: Blood was collected from the ocular sinus of all 
of the animals in each group. ALT (serum glutamic pyruvic transaminase) or AST 
reagent (Teco Diagnostics, Anaheim, CA) was used, and the protocol was altered for use 
in 96-well flat-bottomed microplates. The plate was then read, and the aminotransferase 
concentrations were determined according to the manufacturer's instructions. 
Neural cell culture: The culture of primary hippocampal and cortical neurons was 
performed as described (Huang and Richter, 2007) in neurobasal media (Invitrogen) 
containing B27 supplement (B27 media) and glutamine (1μg/ml). Oligodendrocytes and 
astrocytes were cultured as reported (Albuquerque et al., 2009; Chen et al., 2007) 
AspA activity assay: Mice were sacrificed 3 months after injection, and brain 
homogenates were used for the enzyme assay. Briefly, the brain was homogenized and 
incubated with 50mM Tris–HCl (pH 8.0), 0.5% (w/v) NP-40, 50 mM NaCl, 1 mM 
CaCl2, 2.8 mM NAA in a total volume of 600 µl. After incubation at 37°C for 3-6h, the 
assay mixture was centrifuged and the supernatant was incubated with malic 
dehydrogenase, glutamic oxalacetic transaminase, and NADH for 10 min at 37°C. The 
amount of L-aspartate released was estimated by decrease in absorbance due to the 
conversion of NADH to NAD using a spectrophotometer (Beckman Coulter, DU 800) at 
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340 nm. One milliunit of aspartoacylase activity is equivalent to 1 nmol of aspartate 
released in 1 min. Values were calculated using ANOVA. The value P <0.05 was 
considered significant.  
1
H Magnetic Resonance Imaging and Spectroscopy: Mice were anesthetized with 2% 
isofluorane and constantly monitored for vital signs. All experiments were carried out on 
a Bruker 4.7T/40 cm horizontal magnet (Oxford, UK) equipped with 250 mT/m magnetic 
field gradient and interfaced with a ParaVision 4.0 console. A 1
Proton spectra were fit using LCModel (Version 6.2-2B), which analyzed in vivo 
proton spectrum as a linear combination of model in vitro spectra from individual 
metabolite solutions (Provencher, 2001) and generated data as absolute fits (in 
institutional units) and standard deviations (SD%). Standard deviation was used as a 
measure of the reliability of the fit. The spectral inclusion criteria were SD less than 20% 
for NAA, Cr and Ins.  
H radiofrequency (RF) 
coil configuration (Insight NeuroImaging Systems, MA) with inner diameter (ID) of 4 cm 
was used for the experiments. T2-weighted anatomical images were acquired using a fast 
spin-echo sequence (RARE) (TR=3000 msec, TE=48 msec, matrix size=256×256, 
FOV=2.5 cm×2.5 cm, slice number=16, slice thickness=1 mm). 1H MRS Data was 
acquired using single voxel (Pont Resolved Spectroscopy Sequence (PRESS) (TR=2500 
msec, TE=20 msec, Naverage=1024, voxel size=3 mm×3 mmX3 mm).  
Behavioral studies: For the beam balance test, animals were placed in the middle of a 
horizontal wooden balance beam (1.5 cm × 100 cm) with pads underneath to protect mice 
that fall off the beam.  Latency to fall was recorded, with a 3min time limit for each trial.  
161 
 
Neuromuscular function of the mice was assessed by testing grip strength on an 
inverted screen. Mice were placed in the center of a screen (30 cm2 square-wire mesh, 25 
mm2 holes) until they gripped the mesh. The screen was then inverted above a cushioned 
surface for a 2sec period with the mouse’s head declining. Latency to fall from the screen 
was recorded, with a 2min time limit for each trial.  
Mice were subjected to a rotarod test to evaluate motor coordination and balance. 
Each animal was placed on the rotarod after which speed was adjusted to 3 rpm. The 
latency to fall off the rotarod within this time period was recorded for a fixed speed. 
Animals were also tested for their latency to fall off at accelerated speeds going from 4 to 
40 rpm in 5mins.  
Animals were tested for each experiment 3 times with an inter-trial interval of 
approximately 30 min for each animal and means of 3 trials were used to plot the graphs.  
Transmission Electron Microscopy: Mice were anesthetized and perfused with a solution 
of 2.5 % glutaraldehyde in 0.05 M Sodium Phosphate buffer, pH 7.2. The brain was 
extracted and incubated in 2.5 % glutaraldehyde in 0.05 M Cacodylate buffer overnight at 
4°C. It was sectioned into 1 mm thick sections, rinsed twice in the same buffer and post-
fixed with 1 % osmium tetroxide for 1h at room temperature.  Sections were washed in 
DH2O for 20mins at 4°C and then dehydrated in graded ethanol series of 20% 
increments, before two changes in 100 % ethanol. Sections were infiltrated with two 
changes of 100% propylene oxide and then with a 50%/50% propylene oxide / SPI-Pon 
812 resin mixture overnight.  After three changes of fresh 100 % SPI-Pon 812 resin, 
sections were polymerized at 68°C in plastic capsules. Regions of interest were cut out 
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and thick-sectioned for toluidine blue. Chosen regions were reoriented and approximately 
70nm thin sections were placed on copper support grids and contrasted with lead citrate 
and uranyl acetate. Sections were examined using the FEI Tecani 12 BT with 80Kv 
accelerating voltage, and images were captured using a Gatan TEM CCD camera.  
X-ray Diffraction Analysis: X-ray diffraction was performed as described (Agrawal et 
al., 2009). Briefly, sciatic nerves were dissected from mice sacrificed using isoflurane 
and were maintained in physiological saline (154mM NaCl, 5mM phosphate, pH 7.4) and 
loaded into thin-walled, quartz capillary tubes which were then filled with saline and 
sealed with wax and enamel. X-ray diffraction experiments were carried out using nickel-
filtered, single-mirror focused CuKα radiation from a fine-line source on a 3.0 kW 
Rigaku X-ray generator operated at 40 kV by 10 mA. Exposure times were 30 min. 
Diffraction patterns were collected using a linear, position-sensitive detector (Molecular 
Metrology, Inc., Northampton, MA) and analyzed using PeakFit (Jandel Scientific, San 
Rafael, CA). Myelin period was calculated from the positions of the intensity maxima in 
the diffraction patterns. The relative amount of myelin in each sample was calculated by 
measuring the total integrated intensity of all maxima over background, excluding small-
angle scatter around the beam stop and wide-angle scatter.  
Statistical Analyses: Statistical calculations included Log rank Mantel Cox test for the 
survival table and one way ANOVA followed by Tukey’s Multiple Comparison test for 
all other experiments. *P < 0.05; **P < 0.01; ***P < 0.001, NS not significant.  
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Results 
Restoration of AspA by gene therapy systemically vs. in the CNS alone [IV vs. ICV] 
CD mice mirror the attributes of human patients showing early perinatal lethality 
(>28days) and severe neurodegeneration, hence benefits of a therapeutic intervention 
would be best measured by monitoring longevity of treated animals. Long term survival 
was monitored using the Kaplan-Meier curve for treated mice (n=10 per group) injected 
intravenously [Figure 4.1a, upper panel] as well as intracerebroventricularly [Figure 4.1a, 
lower panel] with all three serotypes. We focused on rAAV9 to compare differences 
between the routes of delivery. Weight gain was monitored daily for the first month 
[Figure 4.1b, upper panel] and subsequently every two weeks [Figure 4.1b, lower panel] 
to compare differences between the routes of delivery using rAAV9 until the animals 
(n=10) caught up with their wildtype (WT) littermates. There was a uniform rescue of 
lethality and extended survival as long as 2 years with all the treated animals and there 
was no significant difference in weight gain between routes of administration. 
As reported earlier, Hematoxylin & Eosin (H&E) staining of brain sections 
showed vacuoles that indicated severe neurodegeneration in untreated CD mice (Ahmed 
et al., 2013) (n=4) at postnatal day 25, P25. These were significantly reduced in mice 
treated both intravenously as well as intracerebroventricularly with rAAV9 [Figure 4.1c]. 
To evaluate changes in vision since CD patients eventually lose their sight, scotopic 
electroretinography (ERG) studies were performed on all groups of mice (n=4) at P90 to 
evaluate retinal response to light flickers as described earlier (Ahmed et al., 2013). 
Electrophysiological measurements of retinal cells produce the ERG trace consisting of 
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a-waves that indicate photoreceptor activity and b-waves that indicate glial cell activity b-
waves [Figure 4.1d]. Both intravenous and intracerebroventricular delivery methods 
correct vision to the same extent (depicted by rAAV9). Cerebral edema is an important 
pathological effect in CD patients and hence MRI was performed to evaluate the status of 
the brain. Intracerebroventricular injections relieved edema to a greater extent than 
intravenous injections delivery methods [Figure 4.1c]. Motor functions were evaluated 
for both the IV and ICV injected animals and even though the latter performed much 
better on all the 4 motor tests, they were not able to sustain the correction over time 
[Figure 4.1f]. Since it seemed that restricting the therapeutic vector to the CNS did not 
allow complete alleviation of the pathology, we tested the animals injected with a 
previously described miRNA-regulated vector genome designed for CNS-restricted gene 
transfer, called rAAV9hAspA(miR-1BS)3-(miR-122BS)3 (i.e. rAAV9hAspA-miRBS) 
which carries 3 copies each of the miRNA binding sites specific to miR-1 and miR-122 
(i.e. miRNAs enriched in heart and skeletal muscle, and liver respectively but not in the 
CNS)(Ahmed et al., 2013). These animals too showed a reduction in motor function 
abilities with the passage of time suggesting an involvement of peripheral tissues in CD 
pathology [Figure 4.2].  
Aspartoacylase is present in peripheral tissues and its deficiency leads to 
morphological and functional abnormalities in multiple peripheral tissues including 
the Peripheral Nervous System 
In order to investigate the importance of AspA in peripheral tissues we used fresh 
tissues from WT mice (n=4) powdered in liquid nitrogen to determine the presence of 
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AspA by qPCR [Figure 4.3a, upper panel] and western blot [Figure 4.3a, lower panel].  
AspA was indeed expressed in varying amounts in different peripheral organs. We then 
examined the morphology of the various peripheral organs starting with their gross 
weight normalized to their body weight [Figure 4.3b, upper panel]. 
We examined the complete differential count of blood (n=5) [Figure 4.3c] to 
discover that diseased mice have lymphocytopenia and a biochemistry profile of their 
serum (n=5) revealed a propensity of these mice for low blood glucose and defective 
pancreatic function evident by amylase levels [Figure 4.3d]. We then examined the effect 
of AspA deficiency on the Central and Peripheral nervous systems by closely examining 
the morphology of the optic, sciatic and vagus nerves by Electron Microscopy studies 
[Figure 4.4a] and myelination status of sciatic nerve by X-Ray Diffraction [Figure 4.4b]. 
We found abnormalities in the myelin structure for all nerves in CD mice validated by the 
myelin period and I2/I3 ratio determined by X-Ray Diffraction studies [Figure 4.4b & c] 
similar to the reported behavior of the optic nerve. The I2/I3 ratio is a measure of the 
relative intensity of 2nd order X-ray reflection over the 3rd order reflections indicating a 
small change in membrane structure This suggests that AspA deficiency does affect the 
peripheral nervous system to a certain extent however the effect may be mild. 
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Figure 4.1 Systemically and intracerebroventricularly delivered rAAV-mediated 
gene therapy rescues lethality and metabolic defects but not motor functions in CD 
mice. (a) Kaplan Meier Survival curves for all groups treated with rAAV9, rAAVrh.8 
and rAAVrh.10 at P0 (n=10) treated intravenously (upper panel) and 
intracerebroventricularly (lower panel)  (b) Early growth rate was assessed by taking 
weights at 2 day intervals for the first month (upper panel) and then at 2 week intervals 
(lower panel) plotted as a function of time. rAAV treated animals were shown as a 
representative of the serotypes.  (c) Hematoxylin & Eosin staining of brain sections 
showing neuropathology. (d) Scotopic ERGs of overnight dark-adapted WT and CD mice 
(n=4 each) to test the response of rods recorded as waveforms (µV) to flickers of light in 
increasing intensity called steps Upper panel, b wave; lower panel, a wave. (e) 
Representative T2 weighted MRI images showing water accumulation (white) in P25 
CD/PBS and P60 GC and WT animals. (f) Motor functions of study groups were tested at 
P30 and P90 based on their performance on the balance beam, inverted screen and 
rotarod moving at fixed (3 rpm) and accelerated speed (4-40 rpm in 5mins). 
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Figure 4.1 Systemically and intracerebroventricularly delivered rAAV-mediated 
gene therapy rescues lethality and corrects phenotype and metabolic defects but not 
motor function in CD mice. 
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Figure 4.2 rAAV gene therapy using miRNA-mediated CNS restriction does not 
cause long-term correction of motor function in CD mice. Motor functions of study 
groups (n=6) were tested at P90 based on their performance on the balance beam, 
inverted screen and rotarod moving at fixed (3 rpm) and accelerated speed (4-40 rpm in 
5mins).WT, wildtype; CD/PBS, CD/rAAV, CD mice treated with PBS or rAAV 
respectively.  
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Figure 4.2 rAAV gene therapy using miRNA-mediated CNS restriction does not 
cause long-term correction of motor function in CD mice.  
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Figure 4.3: Importance of Aspartoacylase in peripheral tissues and general malaise 
in CD mice in addition to CNS pathology. (a) qPCR of Aspartoacylase mRNA and 
representative Western blot for aspartoacylase from fresh tissue homogenates of WT 
animals at P30 (n=4) showing extensive aspartoacylase expression in peripheral tissues. 
(b) Ratio of the weight of peripheral organs normalized to body weight of the animals 
(n=4) from which the tissues were collected; lower panel pictures of gross morphology of 
organs (c) Complete differential count of blood for CD and WT mice (n=4). (d) Serum of 
CD and WT mice (n=4) was tested for various biochemical markers.  
WBC, White blood corpuscles; HCT, Hematocrit; MCV, Mean Corpuscular Volume; 
RBC, red blood corpuscles; HGB, Hemoglobin; MCH, Mean Corpuscular Hemoglobin; 
MCHC, Mean Corpuscular Hemoglobin Concentration; MPV, Mean Platelet Volume; 
PLT, Platelet; ALT, Alanine Aminotransferase; BUN, Blood Urea Nitrogen; Ca, 
Calcium; PO4, Phosphate; Na, Sodium; K, Potassium. 
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Figure 4.3 Importance of Aspartoacylase in peripheral tissues and general malaise 
in CD mice in addition to CNS pathology. 
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Figure 4.4 Examination of the Central and Peripheral Nerves. Nerves were isolated 
from perfused mice and sectioned. (a) Optic, Sciatic and Vagus nerves were processed 
for electron microscopy. Scale bars 200nm . Fresh sciatic nerve was isolated and used for 
X ray diffraction analysis (b) Myelin period and (c) Ratio of I2/I3 was estimated. 
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Figure 4.4 Examination of the Central and Peripheral Nerves. 
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Figure 4.5 Peripheral organs like kidney, muscle and heart reveal abnormalities in 
morphology and functions contributing to additional pathology in CD mice. (a) 
Representative images from H&E stained paraffin sections of the kidney and medulla for 
WT and CD animals (n=4) (b) Electron microscopy of the renal cortex and medulla of 
P21 age matched mice (n=3 for each cohort) (lower panel). (c) Representative H&E 
stained sections of P26 mice where CD animals show more nucleation in muscle fibres of 
the tibialis anterior (TA) muscle (n=3). (d) Neuromuscular junction staining of the TA 
muscle showing several collapsed NMJs in CD mice compared to WT animals (n=3). 
Inset shows higher magnification picture of an individual NMJ. (e) Electrocardiography 
(ECG) trace of WT and CD mice at P21 revealing bradycardia (upper panel) and 
quantitation of the heart wall thickness using Image J using H&E section (3 sections at 
different levels each for n=3 animals per cohort).  
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Figure 4.5 Peripheral organs reveal abnormalities in morphology and functions 
contributing to additional pathology in CD mice. 
 
.   
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We then looked at peripheral tissues beginning with the kidney, which showed 
AspA levels even higher than the brain. Morphologically, H&E stain showed a 
significant difference in the lumen sizes of the kidney tubules [Figure 4.5a] and EM 
studies revealed apoptosing cells in the distal convoluted tubule, loosened filtration 
membranes and loosely structured villi in the proximal convoluted tubule [Figure 4.5b]. 
Since the miRBS vector detargeted therapeutic AspA expression from the muscle, heart 
and liver; we examined these organs in detail. Examination of the skeletal muscle 
histology showed that CD mice show more nucleation [Figure 4.5c]. Staining for the 
neuromuscular junction (NMJ) reveals that in CD mice, some NMJs show denervation 
[Figure 4.5d] and while a majority do not have the healthy pretzel shape but instead are 
collapsed [inset, Figure 4.5d]. 
We then looked at the heart for functional and morphological abnormalities 
[Figure 4.5e]. Electrocardiography (ECG) revealed bradycardia [Figure 4.5e, upper 
panel]. Closer examination of morphology revealed that the size of the heart was larger 
with respect to body weight [Figure 4.3b] and the heart walls were thinner in CD mice 
[Figure 4.5e, lower]. Also abnormalities in the vagus nerve [Figure 4.4a] could be linked 
to the bradycardia. We next examined the liver for structural abnormalities by H&E 
staining and tested serum for AST and ALT levels to check functions. The values though 
significantly different between the WT and CD mice fell within the normal range. In 
summary, the liver did not show any morphological or functional abnormalities [Figure 
4.6a &b]. In addition to these organs we decided to examine the spleen because of its 
abnormally small size [Figure 4.3b]. Phenotyping of splenocytes by FACS revealed that 
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diseased mice have a significantly lower count of several immune cells including but not 
limited to the TCR, CD4 and CD8 cells [Figure 4.3c] and CFSE staining revealed that 
splenocytes of CD mice are unable to proliferate when challenged by CD28 [Figure 
4.3d]. Hence, it appears that the immune system of CD mice is compromised. 
Additionally we examined the eyes for morphological changes by electron microscopy 
since blindness is one of the symptoms of CD patients and untreated mice have defective 
vision (Ahmed et al., 2013). EM analyses of the diseased mice showed disruption of the 
cellular matrix in several retinal layers [Figure 4.3e]. In CD mice, cells in the ganglion 
cells layer had a shrunken appearance while the inner plexiform layer showed an 
abundance of vacuoles. Cells were loosely arranged in the Outer Nuclear Layer. Regions 
like the Outer segment, transition cilia and the transition membrane externa showed 
apoptosing cells and disorganization. 
NAA acts as an inflammatory agent to secondarily result in neurodegeneration  
ICV administration of NAA gave rats seizures (Akimitsu et al., 2000), we decide 
to explore if NAA acts as an inflammatory agent. We performed in vitro studies on 
C57BL/6 bone marrow-derived macrophages that have been immortalized with CreJ2 
retrovirus treating them with increasing concentrations of NAA. We found that 100mM 
NAA kills off the cells whereas lower doses of NAA does induce inflammatory genes 
most notably IL6 [Figure 4.7a]. Interestingly, AspA was upregulated in the macrophages 
presumably to maintain homeostasis. Whole brain homogenates also showed a similar 
trend [Figure 4.7b]. Moreover, since peripheral immune cells showed an abnormal 
phenotype [Figure 4.6c] we decided to explore the immunologically privileged brain for  
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Figure 4.6 Peripheral organs like spleen and eyes but not liver reveal morphological 
abnormalities in CD mice (a) Hematoxylin & Eosin staining of paraffin embedded liver 
shows no morphological abnormality (b) AST and ALT levels were determined using 
serum to determine functional abnormalities of liver. (c) FACS of splenocytes for TCR, 
CD8, CD4 and Treg markers (d) Splenocyte proliferation was monitored by estimating 
dilution of fluorescence of the CFSE dye over a period of 72 hours. Histograms of 
individual animals (n=4) were stacked. (e) Representative images from Electron 
Microscopy studies of the retinal layers of the eyes of WT and CD animals (n=3) Scale 
bars, 1µm. 
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Figure 4.6 Peripheral organs like spleen and eyes but not liver reveal morphological 
abnormalities in CD mice
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Figure 4.7 NAA mediates inflammation in the brain leading to microglia activation. 
(a) In vitro C57Bl/6 macrophages were treated with varying doses of NAA and assayed 
for expression of inflammatory genes and aspartoacylase by qRTPCR. (b) Brain 
homogenates of WT and CD were assayed for inflammatory genes (n=3). (c) Brain 
sections were stained for CD45RO and analyzed under light microscope.  
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Figure 4.7 NAA mediates inflammation in the brain leading to microglia activation.
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Figure 4.8 Examination of blood brain barrier in CD mice. (a) Animals were injected 
with Evans Blue dye alone or in combination with mannitol. After their extremities 
turned blue, animals were sacrificed, perfused with PBS and their brains were isolated 
and photographed. (b) Brain homogenates were assayed spectrophotometrically for 
presence of Evans Blue. (c) Liver was extracted and assayed similarly as a control for 
amounts of dye in the periphery. (d) Amount of Evans Blue in the brain was measured as 
a ratio of body weight. NS, not significant; **P<0.01. 
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Figure 4.8 Examination of blood brain barrier in CD mice. 
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Figure 4.9 Involvement of caspases in CD pathogenesis. (a) Brain lysates were assayed 
for ATP consumption by Cell Titer Glo assay (n=5). (b) Brain homogenates were tested 
for presence of various caspases (n=3 in three experiments) (c) Brain sections were 
stained for cleaved caspase and microglia to test the presence of activated caspase in the 
corpus callosum. Scale 20µm. (d) Microglial cell culture isolated from CD mouse brains 
showed robust expression of cleaved caspase 3. 
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Figure 4.9 Involvement of caspases in CD pathogenesis.
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Figure 4.10 Behavior of in vitro neural cell cultures. (a) Immunofluorescence of in 
vitro primary cell cultures derived from WT mice to determine expression of 
aspartoacylase, AspA. (b) Electron Microscopy of oligodendrocyte cultures derived from 
WT and CD mice. Scale bars 1µm. (c) Electron microscopy of astrocyte culture of CD 
mice. Yellow arrows show centrosomes. Scale bars 0.5µm. 
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Figure 4.10 Behavior of in vitro neural cell cultures.  
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Figure 4.11 Malate-Aspartate Shuttle. Role of aspartate in generation of energy via 
production of NADH. NAD, nicotinamide adenine dinucleotide; NADH,reduced 
nicotinamide adenine dinucleotide, Cyt, cytosolic; Mt, mitochondrial. 
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Figure 4.11 Malate-Aspartate Shuttle.  
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activated microglia using CD45RO staining (Gonzalez-Scarano and Baltuch, 1999). The 
rationale for this was based on the hypothesis that activated microglia can mediate tissue 
damage causing CNS inflammatory disorders leading to neurodegeneration. We found 
profuse signal in the CD brain that indicates that activated microglia are indeed present 
[Figure 4.7c] which may be responsible for the extensive neuroinflammation causing the 
vacuolation in the brain.  
Blood Brain Barrier is not compromised at least at the onset of symptoms in CD mice 
To further explore the molecular pathogenesis of CD, we tested CD mice for permeability 
of their Blood Brain Barrier using Evans Blue (EB) injections. Control mice were 
injected with saline or EB combined with mannitol pretreatment (3ml/100g) since 
mannitol reversibly opens the BBB. Results showed no difference in the BBB 
permeability by appearance of the brain in both WT and CD mice [Figure 4.8a]. 
Spectrophotometric readings from brain homogenates showed no significant difference in 
BBB permeability between WT and diseased animals [Figure 4.8b]. All mice showed 
similar levels of EB retention in the liver [Figure 4.8c] indicating that similar amounts of 
dye was present in circulation. The results indicate that the BBB is not disrupted at least 
in early pathogenesis of CD. Examination of EB retention in the brain with respect to 
body weight (Figure 4.8d) however indicated that there may be more to the story since 
diseased mice weigh almost one-third of their littermates (Ahmed et al., 2013).  
Caspases are upregulated in CD mouse brains and in neural cell cultures 
We also investigated if there was significant loss in cellular components of the 
brain with the white matter degeneration. Cell Titer Glo assay to measure amounts of 
191 
 
actively  metabolizing cells by measuring ATP consumption also did not reveal 
significant differences [Figure 4.9a]. Since degeneration is a major feature in CD we 
investigated if apoptosis was significantly involved. Western blot of brain homogenates 
(n=3) did not show any significant upregulation in protein levels of either the initiator or 
the effector caspases [Figure 4.9b]. Brain homogenates, however, cannot represent 
differences in regional or transient caspase expression. Moreover activated microglia 
could be the source of such caspase expression. Hence, we performed 
immunofluorescence staining for cleaved caspase 3 and Iba1 in whole brain and primary 
cell cultures. We found robust expression of cleaved caspase 3 in microglia and the 
corpus callosum in the brain of CD mice [Figure 4.9c].  
Behavior of primary neural cell cultures isolated from CD mice 
Closer examination of neural cell types in culture revealed several interesting 
observations. First we saw expression of aspartoacylase by immunofluorescence in in 
vitro cultures of both neurons and oligodendrocytes isolated from WT mice [Figure 
4.10a]. By electron microscopy we examined mitochondria in cultured oligodendrocytes 
and found that they were osmolyzed and damaged [Figure 4.10b] similar to that reported 
(Ahmed et al., 2013). Additionally astrocyte cultures from CD mice showed the presence 
of abnormal number of centrosomes [Figure 4.10c], that possibly indicates motility; 
however the implication of this is unknown. 
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Discussion 
Intravenously administered CNS therapeutics requires administration of high 
doses to reach effective drug concentrations at CNS disease sites, resulting in a high 
systemic viral load and an increased manufacturing burden. The cogent next step in viral 
gene therapy targeting the CNS would be a more effective delivery method that lowers 
clinical risk-to-benefit ratio and reduces vector production costs without compromising 
efficiency of vector delivery. Based on our previous successful preclinical study in 
ameliorating CD (Ahmed et al., 2013), we used a 50-fold lower dose using 
intracerebroventricular injections. This would result in high CNS concentrations with 
minimal systemic exposure and toxicity and most importantly cause global CNS 
transduction.  
As intravenous injections of rAAV9 had been efficient in correcting major CD 
symptoms (Ahmed et al., 2013), we primarily examined animals injected 
intracerebroventricularly using AAV9 [Figure 4.1]. In most cases there was no significant 
difference between the two methods of delivery; however, ICV injections showed 
remarkable rescue of edema in the brain [Figure 4.1e]. To our surprise, we found that 
ICV injected animals had a significantly different profile when it came to motor 
functions. In the first month following injection, their motor function performance was 
equivalent to the intravenous treated animals however this declined by 3 months of age 
[Figure 4.1f]. We closely examined if restriction for peripheral tissue had any effect so 
we assessed motor function for older animals injected with the miRNA-BS vector 
described earlier (Ahmed et al., 2013) [Figure 4.2] and found a similar result. This led us 
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to examine if peripheral tissues expressed AspA or showed gross differences [Figure 
4.3b], suggesting that CD may not be corrected by restricting therapeutic vector 
expression to the CNS.  
Aspartoacylase expression has previously been reported in the periphery 
including the kidney and several other organs; however, a detailed analysis was never 
performed (Mersmann et al., 2011; Surendran et al., 2006). Another study reported low 
bone mineral density in CD mice arising as a consequence of the genetic defect 
(Surendran et al., 2003) that would explain the emaciated appearance of the untreated 
mice. Our study sheds light on the importance of aspartoacylase in the periphery through 
a detailed analysis of several organs [Figures 4.5 & 4.6]. Interestingly, we found that 
there was lack of central nucleation but more nuclei in muscle fibers that could be related 
to denervation. This hypothesis seems to be plausible since in the neuromuscular junction 
(NMJ) staining by immunofluorescence we do see a lot of the CD NMJs lacking 
innervation. Moreover denervation could lead to smaller myofiber size, which in turn 
would appear as more crowded nuclei. The function of the malate aspartate shuttle could 
probably be affected by the deficiency of aspartoacylase derived aspartate. Since the 
shuttle would mainly function in gluconeogenesis, the organs involved would primarily 
be the liver. Though we don’t see overt changes in the AST and ALT levels in the liver, 
the glycogen content might be worth a closer examination. Aspartoacylase was reported 
to be expressed in the sciatic nerve (Mersmann et al., 2011) hence we performed an 
extensive analysis on its morphology. Both X-ray diffraction and electron microscopy 
data confirmed that the deficiency of aspartoacylase indeed leads to morphological 
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differences [Figure 4.4]. The enteric nervous system has not been examined however the 
lowered glucose levels in the blood could indicate a role of aspartoacylase in glucose 
metabolism in the small intestine. This seems plausible since the small intestine shows 
high expression of aspartoacylase (Mersmann et al., 2011).It has been widely accepted 
that most CD pathology arises from deficiency of aspartoacylase; however, the damage 
perpetrated by the accumulated NAA cannot be underestimated. Studies have shown 
NAA administration to the rodent brain led to seizures (Akimitsu et al., 2000), which is a 
common symptom in CD patients (Beaudet, 2001). Additionally, the blood CDC revealed 
a disproportionate amount of granulocytes, indicating involvement of the immune system 
[Figure 4.3]. Splenocyte phenotyping by FACS suggests abnormalities in the bone 
marrow or even the thymus suggesting that production of lesser immune cells overall 
would lead to less mature immune cells in the spleen. Closer examination of the splenic 
architecture specifically the size of the pulp regions could shed light on the total 
proportions of immune cells. The lack of proliferation in CD splenocytes when 
challenged by CD28 indicates a lack of T cell response. These cells may be unable to 
proliferate due to a block in metabolism, perhaps in fatty acid synthesis in activated T 
cells. All these data indicate an involvement of the immune system that has never been 
reported before in the context of Canavan disease.  
Since the brain is an immune-privileged organ, the only immune arm would be 
the resident macrophages- the microglia. This prompted us to examine if the accumulated 
NAA, in addition to generation of free radicals (Pederzolli et al., 2009), causes an 
upregulation of immune components secondarily resulting in white matter degeneration 
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and vacuolation. On external supplementation of NAA, interestingly we found an 
upregulation of the IL6 genes in WT macrophages. The results were similar in fresh brain 
homogenates of CD mice indicating that the immune response is another probable cause 
of the severe pathology in CD mice. Studies suggest an involvement of IL6 in the 
induction of autoimmunity (Iwanami et al., 2008) which opens up an interesting avenue 
of explanation for CD neuropathology. Accumulation of NAA may also cause nitric 
oxide toxicity in the brain by upregulation of inducible nitric oxide synthase (iNOS) in 
neurons and endothelia (Surendran and Kondapaka, 2005). Imbalance in NO levels may 
give rise to neurodegeneration (Surendran and Kondapaka, 2005). Upregulation of NAA 
inhibited catalase and glutathione peroxidase activities and increased hydrogen peroxide 
levels (Pederzolli et al., 2010) which suggest a potential role for inflammation. Oral 
administration of NAA in rats led to several symptoms similar to Canavan Disease 
(Delaney, 2010). Our data also suggest that excess NAA may activate microglia via an 
immune response that may result in vacuolization.  
We would expect that the neuropathology and vacuolization would indicate a 
severe loss in cell numbers. To our surprise, we found that the cells present in the whole 
brain have comparable metabolic activities by quantifying the amount of ATP in brain 
lysates [Figure 4.9]. Though activated caspases were not evident in western blots of brain 
lysates [Figure 4.9b], immunofluorescence staining did show up massive upregulation of 
caspase 3 in the brain as well in primary neural cell culture [Figure 4.9b] indicating the 
involvement of apoptosis. The results can be reconciled since analysis of lysates might 
not detect localized or transient upregulation. 
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Another aspect that has been overlooked in the attempt to define CD pathogenesis 
is the characteristics of neural cells from CD mice. It may be argued that a proportion of 
stably transduced neuronal population may be enough to negate the toxicity which would 
probably explain why our previous preclinical therapy extended life to a great extent in 
spite of a single injection. The decline in quality of later life may indicate that the 
turnover of transduced glial cells reduces the overall aspartoacylase making “factories”. 
Again, if neurons are only transduced population, the homeostasis of NAA metabolism 
may be affected. Since the functions of NAA have not been defined it is unknown how 
such a disturbance would affect the brain microenvironment.  Hence we examined the 
individual characteristics of primary neural cultures. Neuronal cultures showed 
expression of aspartoacylase by immunofluorescence. Ultramicroscopic studies of 
oligodendrocytes showed abnormal mitochondria [Figure 4.10b] that resemble lysed 
mitochondria reported in the brain previously (Ahmed et al., 2013). Cell cultures of 
microglia derived from CD robustly expressed cleaved caspase 3 [Figure 4.9d], 
indicating their role in mediating apoptosis. Astrocytes showed the presence of multiple 
centrosomes [Figure 4.10c]; however, the significance of that is not known. As astrocytes 
are essential components of the blood brain barrier (BBB), and astrocytes may link 
spongy neurodegeneration and aspartoacylase deficiency, it was imperative for us to 
examine the BBB permeability of the CD mice more carefully. We did not find the BBB 
to be compromised in the CD mice at least at P20 when the pathology becomes more 
severe [Figure 4.8].  
An important fact is that aspartate generated by the action of aspartoacylase has 
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very important implications in the energy metabolism in addition to it being a 
neurotransmitter (Cavallero et al., 2009). The aspartate-malate shuttle is an essential 
aspect of glucose metabolism in the cell [Figure 4.11]. Aspartate and glutamate are 
closely linked with each other through transaminase reactions (Cooms, 1997). Glutamine 
produced by astrocytes is used by neurons to produce glutamate in the glutamine-
glutamate cycle (Newsholme et al., 2003). In astrocytes, the α-amino group of glutamate 
is transferred to oxaloacetate to yield aspartate by the catalysis of aspartate 
aminotransferase (Yudkoff et al., 1986). Aspartate aminotransferase [E.C 2.6.1.1] is 
involved in the aspartate-malate shuttle [Figure 4.11] that is essential in generating 
glucose and glutamate and occurs between the cytosol and mitochondria. Lack of 
aspartate may compromise the shuttle and lead to a decrease in glucose metabolism as 
observed in our serum biochemistry panel [Figure 4.3d]. Low blood glucose could also 
stem from issues in digestion that may possibly be caused by enzymatic defects or 
abnormalities in the intestine. 
Increasingly, it seems that CD pathogenesis might not be confined to the CNS but 
may also involve pathogenesis of the peripheral organs which is also essential for future 
therapeutic strategies. A lower dose of vector does indeed alleviate the severity of 
symptoms but is not palliative, indicating the need for more powerful codon-optimized 
vectors and dose-escalation studies of the same to elucidate the best means of targeting 
disease models that can be translated to clinical therapeutics. 
In conclusion, our study highlights the involvement of peripheral tissues in a 
primarily neurological disorder. We also suggest NAA-induced immune responses as a 
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likely mechanism for CD pathogenesis. In short our study points out new guidelines to be 
considered while designing newer and better therapeutics to target this fatal disease. 
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CHAPTER V: FINAL SUMMARY AND CONCLUDING REMARKS 
 The work in this Thesis investigates the development of an efficacious gene 
therapy strategy for the fatal pediatric autosomal recessive leukodystrophy Canavan 
disease. These studies first explore possible vectors to be used for such therapeutic 
applications and then translated them into preclinical applications in a bona-fide mouse 
model for the disease. The results of these investigations have a direct bearing in 
development of clinical therapeutics for afflicted patients. They also proffer a platform to 
investigate the molecular pathogenesis of the disease that will result in better and more 
efficacious palliative measures 
Chapter II reports several rAAVs are capable of crossing the Blood Brain Barrier 
and transducing the CNS cells in both neonates as well as in adults. The ability of rAAVs 
to transduce amounts of neuronal cells in different regions may be relevant for treating 
neurological diseases such as spinal muscular atrophies (Suzuki et al., 2009) and neuronal 
ceroid lipofuscinoses (Hobert and Dawson, 2006). Transduction of astrocytes by rAAVs 
expressing secreted neurotrophic factors may be also beneficial for a number of 
neurodegenerative diseases such as Canavan disease (Kumar et al., 2006). Potential 
clinical application of intravascular rAAV-mediated gene delivery extends to the 
peripheral nervous system (Federici and Boulis, 2007). Efficient transduction of dorsal 
root ganglia may open new therapeutic possibilities for patients suffering from chronic 
pain  (Beutler, 2010). From any of these perspectives, transduction patterns generated 
from our study may serve as initial proof-of-concept data for diverse neurological 
disorders. Our findings hold considerable clinical significance for gene therapy of CNS-
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related disorders, especially for young patients. For a variety of neurological diseases, 
treatment during infancy will be necessary to prevent irreversible CNS injury. 
rAAVrh.8 and rAAVrh.10 emerged as potent vectors with multiple strong areas 
of CNS transduction that can be developed into therapeutic strategies. Robust 
transduction throughout the spinal cord, brainstem, and cortex are characteristics 
desirable for treatment of disease with global CNS pathology like Canavan disease. 
Notably, rAAV9 displays similar transduction qualities in the spinal cord of adult mice 
by intravenous injection, as reported previously (Duque et al., 2009),  although it ranked 
slightly below the performance of rAAVrh.8 in side-by side comparisons [Figures 2.6 & 
2.7]. However, a direct comparison with previously published data is often complicated 
due to possible differences in vector production, dose, and quantification methods. 
Canavan Disease (CD) falls in a category of diseases, which if treated, could have 
wide implications in developing therapeutics for a vast group of leukodystrophies and 
neurodegenerative diseases. Being a monogenic defect, CD is a perfect target for gene 
therapy, which could also be utilized as tools to tease out the underlying pathology of 
leukodystrophies and develop efficient therapeutics for them. Mouse models that show a 
less severe phenotype resembling infantile and juvenile CD patients could be used to 
determine disease progression. Additionally, the unique symptom of elevated NAA levels 
in CD also makes it a perfect disease model to study functions of NAA. 
Chapter III and IV document the development of efficacious therapeutics for CD 
using the AspA−/− KO mouse model. The AspA−/− mouse model in SV129/Ev 
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background is a stringent preclinical model for the severest form of CD. In chapter III, 
investigations clearly demonstrated the feasibility of completely rescuing the early 
lethality, slowing down the disease progression, and extending the survival of CD mice 
as well as address off-target transgene expression in peripheral tissues using systemic 
delivery of rAAVs that can cross the BBB. The crucial role of AspA in myelination and 
early neurodevelopment as well as the feasibility of treating CD by CNS-targeted gene 
therapy using systemically delivered rAAVs is also highlighted. Chapter IV describes a 
more effective delivery method and lower vector dosage, reducing the clinical risk-to-
benefit ratio and vector production costs. The study focuses on intracerebroventricular 
delivery as a possible improvement on delivery system to the CNS where global CNS 
delivery is achieved without affecting the peripheral tissues. The study however indicated 
that a systemic therapeutic measure is needed for effective alleviation of Canavan disease 
symptoms since the data indicated the involvement of peripheral tissues in a primarily 
CNS disorder. Additionally it also reports the probable activation of the immune system 
presumably caused by NAA accumulation secondarily causing vacuolation, a phenotype 
in the disease.  
To achieve basic molecular understanding of CD pathogenesis, it is interesting to 
note that patients with mutations in the functionally similar aminoacylase I (hydrolyses 
N-acylated /N-acetylated amino acids (except L-aspartate)) have overlapping clinical 
features like encephalopathy, seizures, psychomotor dysfunction, hypotonia, and 
sensorineural hearing loss as well as excretion of N-acetylated amino acids in the urine. 
We report aspartoacylase expression in neurons both in the brain as well as in culture, 
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which was not reported before. From a cellular standpoint, to date, most of the expression 
and subcellular localization data for aspartoacylase have used a single RNA probe or 
single antibody which may fail to detect differences among aspartoacylase isoforms 
including aminoacylase I. An important element for translating observations from CD 
mice is coupling in vivo physiology and imaging in the mouse to functional neuroimaging 
in patients to help identify conserved neural circuit phenotypes and pave way to improve 
upon therapeutics.  
In addition to existing therapeutic modalities, alternative means of treatment for 
CD could include partial silencing of the NAA biosynthetic enzyme AspNAT 
(Madhavarao et al., 2003) to control the NAA metabolism cycle. Additionally inhibition 
of NAA export from the neuronal mitochondria could markedly decrease NAA 
accumulation in interstitial spaces that probably causes osmotic dysregulation in the 
CNS. Pharmacological protection of oligodendrocytes against damage in demyelinating 
diseases could also be a promising avenue of treatment (Waksman, 1999). Intravenous 
delivery of rAAV9 (Ahmed SS, 2013) in the CD model suggests that lowering NAA 
levels in the brain probably led to alleviation of NAAduria as well as a decrease in edema 
indicating that the MWP theory could partially explain pathogenesis. 
The utility of these newer AAVs is not confined to clinical application; systemic 
gene delivery to the CNS should also be useful as a convenient method to manipulate 
gene expression in the course of basic neuroscience research. Effective and stable 
transgene expression in the CNS by intravenous administration of rAAVs may be applied 
to establish somatic transgenic animal models, which is a potentially cheaper, faster, and 
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simpler method than conventional transgenesis. Somatic CNS gene knockdown animal 
models may also be created using the method described here (Siegel and Callaway, 
2004). The field currently seems poised for more revolutionary progress with the advent 
of newer serotypes and advances in capsid evolution for rAAVs that are specific for 
different neural cell types and can cross the BBB. It is worthwhile to point out that the 
grouping we introduce should not be interpreted as if there are absolute boundaries 
between the groups, but rather, it is used as a means to facilitate the description of the 
large number of AAV serotypes tested and to provide a useful guide for selecting the 
most suitable vectors in future experimentation. 
It should be noted however, in spite of newer serotypes there will still remain the 
issue of half-life of the transduced cells. All of these factors increasingly indicate the 
potential for combinatorial therapy strategies that could be translated to human patients. 
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